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Bacteria use receptor histidine kinases to sense extracellular cues and
convert them into intracellular signaling events that allow them to respond to
their environment. In Staphylococcus aureus, each individual cell must sense the
size of its overall population in order to synchronize virulence factor expression
with the entire population. This task is carried out by the accessory gene regulator
(agr) quorum sensing system. The agr autoinducing peptide (AIP) pheromone
activates the AgrC receptor histidine kinase, resulting in downstream
modulation of virulence factor expression. As S. aureus is a dangerous pathogen,
understanding virulence regulation is of great interest, and the agr system has
been extensively studied. However, little was known about the mechanism of
ligand-induced signal transduction by AgrC at the outset of this work. Moreover,
AgrC is member of a unique class of histidine kinases, for which the activation
mechanisms are equally speculative, although several of these receptors function
in important quorum sensing processes. The aim of this work was to elucidate
molecular mechanisms of AIP–AgrC signaling, focusing on inhibitor structure–
activity relationships and understanding how ligand binding results in AgrC
kinase activation. A new Fmoc-based synthetic route to AIPs and -thioester
peptides was developed and used to construct a series of inhibitor AIPs to define
the minimal inhibitory pharmacophore. The minimized scaffold should provide
a foundation for future medicinal chemistry efforts. The AgrC activation
mechanism was probed via direct biochemical analysis of the receptor, which

was previously unattainable, and mutagenesis. The results indicate that AgrC is
a dimer and trans-autophosphorylates and that signal transduction occurs
symmetrically within the dimer due to intermolecular conformational changes.
This mechanism may be a general means by which dimeric quorum sensing
receptors rapidly elicit a response upon signal detection.
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Chapter 1: Introduction
1.1 The Regulation of Virulence in a Superbug
Staphylococcus aureus is an opportunistic pathogen and a major health
threat worldwide. S. aureus is part of the commensal microbial flora of
approximately 30% of the adult population and only becomes pathogenic if the
bacteria are given the opportunity to invade mucous membranes or soft
tissue (1). Most infections are cleared by the immune system or treatable with
antibiotics; however, a weakened immune system, surgery, and implanted
medical devices are risk factors for potentially fatal infections (2). Thus, S. aureus
thrives in hospitals, where vulnerable patients being treated for an unrelated
problem may become infected with their commensal strain or with a strain
spread in the hospital; and infections that advance too quickly for successful
antimicrobial treatment and/or are resistant to multiple antibiotics often prove
fatal. Methicillin resistant S. aureus (MRSA) are multidrug resistant bacteria that
were first isolated in 1961 and are now estimated to be responsible for over
18,000 deaths in the United States per year (3). Furthermore, while nosocomial
MRSA are the leading cause of fatal infections, the incidence of communityacquired MRSA is also increasing at an alarming rate (4). The only antibiotic
against which S. aureus has not gained widespread resistance is vancomycin; but
in 1999, the first incidences of S. aureus infection with intermediate vancomycin
resistance (VISA) were reported in the U. S. (5, 6). Therefore, much attention is
focused on preventive measures, responsible use of antibiotics to slow the
development of resistance, and development of new treatments to combat this
growing problem (7-9). Key to these important efforts is to further our
understanding of S. aureus virulence and pathogenesis.
1

S. aureus is an especially dangerous pathogen due to the relatively fast
host-to-host transmission rate of virulent strains compared to avirulent
strains (10), its ability to acquire antibiotic resistance, and its large, diverse
arsenal of virulence factors that make it both uniquely adept at evading the host
immune system and very toxic. Although disease is the very unfortunate
outcome for the host, the sole function of virulence factors is to enable the
bacteria to survive in the hostile conditions of the host environment (11). There
are two main classes of virulence factors, each associated with different phases of
population growth (Figure 1) (1). During the lag and exponential phases, S.
aureus cells produce cell wall-associated factors that facilitate tissue attachment
and evasion of the host immune system, allowing the bacteria to accumulate and
possibly form a biofilm. For example, microbial surface components recognizing
adhesive matrix molecules (MSCRAMMS) adhere to the extracellular matrix to
give the bacteria an attachment point in the host. Protein A binds IgG antibodies
that form a protective coat and hide them from the immune system. Once the
population size is sufficient, the cell wall-associated factors are down-regulated
in late exponential phase and stationary phase, allowing the bacteria to detach
from their original colonization site and establish an invasive infection. At the
same time, the bacteria secrete enzymes and toxins, termed exoproteins, to
degrade host tissue and to promote spread of the infection. The degradative
enzymes include proteases and hemolysins, which lyse red blood cells by
creating pores in the cell membranes or by hydrolyzing membrane lipids.
Enterotoxins are the causative agents of S. aureus food poisoning and contribute
to toxic shock syndrome and other diseases by stimulating T-cells to produce
proinflammatory cytokines in excessive amounts (1, 11).
2



Figure 1. Coordination of Virulence Factor Expression with S. aureus
Population Growth. Adapted from (11). During exponential growth, cell surfaceassociated virulence factors are highly expressed in order to promote attachment
to the host extracellular matrix and evasion of the host immune system. In
stationary phase, the cell surface-associated virulence factors are down-regulated
and expression of secreted exoproteins is induced to promote invasion of the
host and impart toxicity. The bacteria sense the increase in population density
via the agr system, which is activated at the transition between exponential and
stationary phases and regulates expression of these two classes of virulence
factors.
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The accessory gene regulator (agr) system of S. aureus coordinates
production of the two main classes of virulence factors with different phases of
growth, in many cases by directly modulating their expression levels (12, 13).
While agr is thus considered to be a global regulator of virulence, it is one of
several genetic loci connected in a complex signaling network that precisely
regulates the staphylococcal virulon (Figure 2) (14-17). The staphylococcal accessory
regulator (sar) is an important regulator of virulence that mediates many of its
effects by influencing agr expression: SarA, SarU, and SarR up-regulate agr
transcription; contrarily SarR and SarT indirectly down-regulate agr by
repressing expression of SarA and SarU, respectively; and some Sar proteins
regulate virulence factors independently of agr. In a variety of infection models,
loss of function mutations in either agr or sar exhibit reduced virulence, and the
virulence of double agr- sar- mutants is, in some models, further reduced (18-21).
However, the precise role of agr in the establishment of infection is unknown.
Other important loci include S. aureus exoprotein expression (sae) (22), which may
act downstream of agr to maintain hemolysin and coagulase expression (23),
staphylococcal respiratory response (srr), which is required for optimal growth in
anaerobic conditions and inhibits agr output (24), and repressor of toxins (rot),
which counteracts many effects of agr but also induces expression of some
exoproteins (25-27).
The agr response synchronizes virulence factor expression among all
members of the staphylococcal population via a bacterial communication
mechanism called quorum sensing. The ability to communicate is essential for
bacteria to carry out many fundamental group functions, including virulence,
competence, bioluminescence, and biofilm formation (28). Quorum sensing
4


 



  
  

 
   



 


 

 

  



 









Figure 2. Network of Genetic Loci that Control Virulence in S. aureus. The
expression of virulence genes such as -hemolysin (hla), -hemolysin (hld), other
exotoxins, and Protein A (spa) is modulated by a complex, interactive network of
many regulatory loci, including agr.
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systems facilitate these processes by allowing each individual bacterium to sense
the density of the entire population of which it is a member. Bacteria
constitutively secrete signaling molecules known as autoinducers that
accumulate to concentrations proportional to the bacterial population density in
a closed system. An autoinducer activates its target only after reaching a certain
threshold concentration, at which point it triggers a specific, coordinated
response through target gene transcription. Consequently, activation of
energetically demanding processes is limited to instances in which there are
enough bacteria present to elicit the desired effect. In Gram-positive bacteria
such as staphylococci, the autoinducers are short peptides, often bearing posttranslational modifications, called autoinducing peptides (AIPs) (28). At
concentrations indicating a quorum, each AIP binds its corresponding receptor,
resulting in either activation or inhibition of target gene transcription. In
staphylococci, quorum sensing for coordinated virulence factor production is
mediated by the agr AIP and signaling system (29, 30).
The agr signaling system is a canonical two-component system (TCS).
TCSs are ubiquitous in bacteria, allowing them to sense and react to a variety of
stimuli,

including

osmolarity,

pH,

oxygen,

chemoattractants,

and

autoinducers (31). Each TCS is typically composed of a receptor histidine protein
kinase (HPK) that senses the signal and a response regulator (RR) transcription
factor that modulates gene expression. The HPK receptors are typically dimeric
and consist of a sensory domain and an histidine kinase (HK) domain, which is
further divided into two subdomains: an -helical coiled-coil region containing
the dimerization interface and histidine phosphorylation site (DHp), and the
catalytic kinase domain (CA) (32). Stimulus perception by the sensory domain
6

triggers activation of the HK domain, resulting in trans-autophosphorylation of
the contralateral histidine and phosphotransfer to a conserved aspartate in the
associated RR.
The agr locus contains two divergent promoters, P2 and P3, which
modulate transcription of RNAII and RNAIII, respectively (Figure 3A) (30).
RNAII encodes the agr TCS and two genes required for AIP biosynthesis. AgrB is
an integral membrane protein required to process the AgrD propeptide, resulting
in secretion of a mature AIP that contains a thiolactone macrocycle formed
between a conserved cysteine sulfhydryl group and the -carboxylate (19, 29).
AgrC is a polytopic HPK that autophosphorylates and activates the AgrA RR
upon binding to the AIP. AgrA then binds and activates transcription at the P2
and P3 promoters (30, 33), resulting in a positive feedback loop and RNAIII
transcription. RNAIII is the -hemolysin mRNA and a regulatory RNA that
modulates expression of many virulence factors (13, 34). In addition to RNAII &
III of the agr locus, AgrA was recently found to directly activate transcription of
proinflammatory, leukolytic peptides that enhance virulence called phenolsoluble modulins (PSMs), demonstrating that RNAIII is not the sole effector of
the agr response (35, 36).
The agr locus, conserved among the staphylococci and with homologs in
many other species, has undergone an interesting evolutionary divergence,
giving rise to variant specificity groups, of which there are four in S. aureus and
two or more in several other staphylococcal species (37-39). The sequence
variability of each agr specificity group is contained within agrB, agrD, and the
transmembrane sensor domain of agrC (Figure 3B), while agrA and the HK

7
















   

  


 













  











  










 

  












  












  

        








Figure 3. The agr Locus and Variation of the Four Specificity Groups. (A) The
AgrD propeptide is processed and secreted, in part, by AgrB to form the mature
AIP. At the appropriate AIP concentration, the AIP binds the sensor domain of
the receptor histidine kinase, AgrC, resulting in autophosphorylation and
phosphotransfer to AgrA. Phosphorylated AgrA activates transcription at the agr
P2 and P3 promoters, resulting in a positive feedback loop of the agr system and
RNAIII transcription, which mediates many downstream effects. (B) The
sequence variation among the four agr groups is contained within agrB, agrD,
and the sensor domain of agrC. The sequences and structures of the four AIPs are
shown.
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domain of agrC are identical across all four S. aureus agr groups. Each S. aureus
agr group synthesizes a distinct AIP of seven to nine amino acids, which activates
the cognate AgrC receptor, and the group identity of the AgrC sensor domain
alone dictates the specificity of AIP recognition for any given population (40).
Remarkably, cross-group AIP–AgrC interactions are inhibitory (37), with
heterologous AIPs acting as competitive antagonists (41) and/or inverse
agonists (42). The only exception to this intergroup interference is the crossactivation observed between groups I & IV, the AIP sequences of which differ by
just a single amino acid. Intraspecies quorum sensing interference may be unique
to S. aureus, as cross-group inhibition has not been observed among the three
known agr groups of S. epidermidis (39). The in vivo relevance and therapeutic
implications of this intriguing phenomenon are poorly understood and the
subject of ongoing study in several laboratories; nevertheless, cross-group
antagonism is a valuable tool for studying AIP structure-activity relationships
and makes agr an especially attractive model system for the study of quorum
sensing in Gram-positive bacteria.
1.2 Molecular Mechanisms of the agr System
The agr system is one of the most extensively studied quorum sensing
systems, and the work of several labs has provided a relatively detailed picture
of the molecular mechanisms of this pathway. The understanding of this system
is nonetheless a work in progress, and the following section details what is
known as well as gaps in knowledge that are yet to be filled.
1.2.1 AIP Biosynthesis
Significant progress has been made toward elucidating the mechanism of
AIP biosynthesis since the initial 1997 report that AgrB is involved (29). Given
9

that the AIP sequences are nested within the AgrD precursors of all four agr
groups (Figure 4A), processing of each AgrD propeptide to form a cyclic AIP
requires three chemical transformations: two proteolytic cleavage steps and
thiolactone formation. The order of the two cleavage events and at least some of
the proteases involved are now known, but the mechanism of thiolactonization
remains purely hypothetical.
The first proteolytic step removes the C-terminal tail of AgrD and is
mediated by AgrB, as determined by western blot analysis of crude lysates
containing

epitope-tagged

versions

of

AgrD

(43).

The

intermediate

corresponding to the N-terminal portion of AgrD plus the AIP sequence was
observed only when AgrB was present, and the C-terminal AIP–AgrD fragment
was not detected. If AgrB indeed functions as a protease, then one would expect
to find conserved catalytic residues in the protein. There are in fact several
conserved histidine, serine, and cysteine residues that potentially fit the bill.
Mutagenesis experiments found that two of these residues, His77 and Cys84, are
required for production of an active AIP (43). According to a topological model
of AgrB (44), His77 and Cys84 are located on or near the cytoplasmic face of the
protein, making them potentially accessible to AgrD (Figure 4B). Thus, AgrB
may be a cysteine protease, although definitive proof of this hypothesis awaits
further biochemical characterization of the purified protein.
After years of speculation that other proteins in addition to AgrB may be
involved in AIP production (43-45), a recent study finally revealed that SpsB, a
type I signal peptidase, carries out the second cleavage event of AgrD-I,
removing the N-terminal region (46). A synthetic group I peptide substrate,
NIAAYST tagged with fluorescein, was added to various lysate fractions, and the
10


 

 












 



  

   

   



  

   



 

 





  



 












































 




















































































 

Figure 4. AgrD Sequence Alignment and Proposed Mechanism of AIP
Biosynthesis. (A) AgrD sequences with the AIP portions in green and conserved
residues shaded yellow. The N-terminal P sites are numbered. (B) Proposed
mechanism of AIP biosynthesis. The AgrB (38) topology is based on Zhang et al.
(44). C-terminal cleavage of AgrD (green) is mediated by His77 and Cys84 of
AgrB to yield an acyl-enzyme intermediate, which is released via intramolecular
transthioesterification. Translocation by an unknown mechanism allows Nterminal cleavage by the serine signal peptidase SpsB (44), via a serine/lysine
catalytic diad (star). The structure is a homologous peptidase from B. subtilis (47).
11

cleavage products were identified by comparing their agarose gel retention times
to synthetic standards. Through a series of fractionation and inhibition
experiments, the proteolytic activity was attributed to the type I signal peptidase
SpsB. The role of SpsB or other peptidases in the processing of the group II, III,
and IV AIPs is yet to be determined. SpsB is identical in all agr groups, but the
residues N-terminal to the AIP sequence within AgrD are not (Figure 4A).
There is a conserved Asp-Glu motif immediately following each
embedded AIP sequence, and this acidic motif presumably acts as the
recognition site for cleavage by AgrB. However, the molecular determinants
underlying N-terminal processing are less obvious from sequence analysis. The
N-terminal region of each AgrD peptide contains a putative amphipathic helix
that anchors AgrD to the membrane, and specific processing of AgrD by AgrB is
maintained even when all residues N-terminal to P10 of AgrD are replaced with
an unrelated amphipathic helical sequence (48). There is a conserved Ile-Gly
motif just N-terminal to each AIP sequence, but since the lengths of the AIPs
vary, it is separated from the site of cleavage by a different number of amino
acids in AIPs-I/IV, II, and III (Figure 4A). Moreover, the substrate used in the
study that revealed the involvement of SpsB in N-terminal processing of AIP-I
did not include the Ile-Gly motif (46). Important sequence requirements for
cleavage by SpsB are a basic or hydrophobic residue at P2, a proline at P5 that
induces a helical turn (49), and possibly an alanine at P1 (50). All four N-terminal
AgrD sequences contain a hydrophobic residue at P2 and a glycine (of the Ile-Gly
motif) at or adjacent to P5 that might induce a turn (Figure 4A). However, the P1
and P3 residues are also hydrophobic in most cases, and the position of the
glycine is not consistent in each AgrD sequence as noted above. Furthermore,
12

only AgrD-I has an alanine at P1. Thus, either AgrD contains additional
recognition elements that are not evident in its primary structure or proteins
other than SpsB cleave the N-terminus of AgrD in groups II, III, and IV.
The group specificity of AgrD processing by AgrB is not as rigid as that of
AIP–AgrC interactions. While AgrB can only process the cognate AgrD in most
cases, group III AgrB (AgrB-III) can process AgrD-I to form an activator of AgrCI, and AgrB-I can process AgrD-III to form an inhibitor of AgrC-I (37). AgrB-I & IV may also be capable of processing both AgrD-I & -IV, as the sequences of
these two groups are very similar, but this hypothesis has yet to be tested. In an
effort to understand the basis for AgrB–AgrD specificity, Zhang et al. constructed
a panel of AgrB-I/II chimeras by swapping homologous segments of the two
proteins, then determined their ability to synthesize active AIPs from AgrD-I & II
in a reporter assay (51). The authors narrowed down the determinants of
specificity in AgrB-I to amino acids 43 to 67 and to residues 126 and 141 in AgrBII. While the lack of expression and localization data for the mutant proteins is a
caveat of this study, it is nonetheless interesting that the specificity determinants
for AgrB-I and AgrB-II appear to be in different regions of the primary sequence.
Further study will be needed to reveal the how these patches impart specificity
and which features of the AgrD propeptides they recognize.
Based on all of the studies reviewed above, the working model of AIP
formation is shown in Figure 4B. First, AgrD anchors to the membrane and is
recognized by AgrB, which generates an acyl-enzyme thioester intermediate
upon nucleophilic attack by the catalytic cysteine. Transthioesterification by the
conserved AgrD cysteine mediates release from AgrB. The resulting N-terminal
AgrD–AIP thiolactone intermediate is transported through the membrane by
13

AgrB or an unknown protein and cleaved by the SpsB signal peptidase, releasing
the mature AIP into the extracellular milieu. While the proposed concomitant
amidolysis, transthioesterification mechanism is appealing, the final word on this
fascinating maturation process awaits the development of a reconstituted
AgrB/AgrD system.
1.2.2 AIP Structure-Activity Relationships
A large effort has been made toward determining the structure–activity
relationships of the four AIPs by employing synthetic methods and a rapid,
quantitative agrP3::blaZ reporter assay (19, 29, 40, 41, 52-54). Efficient chemical
synthesis of AIPs combine solid-phase peptide synthesis (SPPS) and solution
phase chemistry (19, 52, 53). In the most efficient protocol using Boc chemistry,
the linear peptide is first synthesized by SPPS on an -thioester-generating resin,
then cleaved from the solid support, and the final AIP product is obtained by
spontaneous transthioesterification of the unprotected peptide -thioester in
neutral aqueous solution (52) (Figure 5). Synthetic AIPs are extremely potent
agonists and antagonists of cognate and non-cognate AgrC receptors,
respectively, with EC50 and IC50 values in the low nanomolar range (19). The
recognition determinants for agonism are much more stringent than those for
antagonism, consistent with the requirement for group-specific AIP–AgrC
interactions for activation but not inhibition (19, 40, 53). For example, the
exocyclic “tail” residues are dispensable for inhibition but not activation (19, 40).
Indeed, some truncated AIPs consisting of only the pentapeptide macrocycles
inhibit all four S. aureus AgrC receptors, including the cognate AgrC (Table 1).
Furthermore, replacement of the AIP thiolactone linkage with a lactam or lactone

14

Table 1. Structure-Activity Relationships of AIPs Made Prior to this Work.
AIP
Derivative
AIP-I
AIP-II
AIP-III
AIP-IV
AIP-I–II
AIP-II–I
AIP-II
Lactone
AIP-II
Lactam
trAIP-II
trAIP-I
trAIP-IV
trAIP-I/IV
2A
AIP-II G1A
AIP-II V2A
AIP-II N3A
AIP-II S6A
AIP-II S7A
AIP-II L8A
AIP-II F9A
AIP-I Y1A
AIP-I S2A
AIP-I T3A
AIP-I/IV 5A
AIP-I/IV 5N
AIP-I/IV 5F
AIP-I F6A
AIP-I I7A
AIP-I M8A
AIP-I M8I
AIP-III 8 AA
AIP-III 9 AA

AIP
Sequence
YSTCDFIM
GVNACSSLF
INCDFLL
YSTCYFIM
YSTCSSLF
GVNACDFIM
GVNASSSLF

AgrC Activation
I
II
III
IV
+++
–
–
+
–
+++
–
–
–
–
+++
–
++
–
–
+++
–
–
–
–
–
–
–
–
–
–
nt
nt

AgrC Inhibition
I
II
III
IV
–
+++ +++
–
+++
–
+++ +++
+++ +++
–
++
–
+++ +++
–
+++ ++ +++ +++
++ +++ ++
+
+++
–
nt
nt

GVNA(Dapa)
-----SSLF
CSSLF
CDFIM
CYFIM
CAFIM

–

+

nt

nt

+++

–

nt

nt

–
+
–
–

–
–
–
–

–
–
–
–

–
–
–
–

++
+
++
+++

++
+++
+++
+++

+++
++
+++
+++

++
–
+
+++

AVNACSSLF
GANACSSLF
GVAACSSLF
GVNACASLF
GVNACSALF
GVNACSSAF
GVNACSSLA
ASTCDFIM
YATCDFIM
YSACDFIM
YSTCAFIM
YSTCNFIM
YSTCFFIM
YSTCDAIM
YSTCDFAM
YSTCDFIA
YSTCDFII
YINCDFLL
AYINCDFLL

–
–
–
–
–
–
–
++
+++
++
–
+++
+++
+
+
+
+++
nt
nt

+++
++
–
+++
+++
–
–
nt
nt
nt
–
–
–
nt
nt
nt
–
nt
nt

nt
nt
–
nt
nt
nt
nt
nt
nt
nt
–
++
–
nt
nt
nt
–
–
–

nt
nt
–
nt
nt
nt
nt
nt
nt
nt
–
–
+++
nt
nt
nt
++
nt
nt

+++
+++
+++
+++
+++
–
–
–
–
–
+++
–
–
–
–
–
–
++
nt

–
–
++
–
–
–
–
nt
nt
nt
+++
+++
+++
nt
nt
nt
+++
nt
nt

nt
nt
+++
nt
nt
nt
nt
nt
nt
nt
+++
–
+++
nt
nt
nt
+++
++
++

nt
nt
+++
nt
nt
nt
nt
nt
nt
nt
+++
+++
–
nt
nt
nt
–
nt
nt

+, ++, +++ = weak to strong activity. – = no activity detected. nt = not tested.
Dapa = diaminopropanoic acid. trAIP = truncated AIP. AA = amino acids.
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Figure 5. AIP Synthetic Route via Boc-Based Solid Phase Peptide Synthesis. A
mercapto-propionic linker is synthesized on resin, and coupling of the Cterminal amino acid results in thioester formation. Chain elongation is achieved
with standard Boc-based solid phase peptide synthesis (SPPS) conditions, The
peptide is cleaved from the resin with anhydrous HF and cyclized via
intramolecular transthioesterification upon addition of aqueous buffer at neutral
pH. The synthesis of AIP-II is shown as an example.
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causes a dramatic reduction in agonistic potency but has virtually no effect on
antagonism (19, 53). However, linear versions of the AIPs are completely
inactive, demonstrating that a macrocyclic structure is one requirement for
inhibition as well as for activation (19). The presence of two bulky hydrophobic
residues at the C-terminus, a strongly conserved feature of the staphylococcal
AIPs (Figure 6), also seems to be critical for binding and activity since alanine
substitutions at either of these positions in AIP-II result in a dramatic reduction
in agonist and antagonist potency (19). Thus, the macrocycle and hydrophobic
motif are important for bioactivity, and the thioester and tail residues are
additionally required for receptor activation but not for binding or inhibition.
While all four S. aureus AIPs follow the general paradigm described
above, determinants of specific AIP–AgrC interactions vary considerably among
the different groups. Alanine scanning mutagenesis revealed that the key
residues for receptor activation lie in different positions in the sequences of
different AIPs (19, 53). For example, Asp5 of AIP-I, which lies in the macrocycle,
and Asn3 of AIP-II, which is in the tail, are critical determinants for specific
activation of the corresponding AgrC-I & -II receptors. Loss of these side chain
functionalities in the AIP-I D5A and AIP-II N3A mutants results in loss of
specificity but not activity, as the mutant peptides maintain antagonism of noncognate AgrC receptors and are converted to antagonists of their cognate
receptors (Table 1). Conversely, substitution of an amide for the acid in AIP-I
D5N unexpectedly converts the peptide to an AgrC-III agonist (52). Finally, nonnative appendages, such as biotin, can be conjugated to the N-terminus of AIP-I
without significantly affecting activity, but the addition of one amino acid to the
N-terminus of AIP-III leads to a loss of agonism (52).
17

Figure 6. Sequence Alignment and Hydrophobicity Profiles of Known and
Predicted Staphylococcal AIPs. Polar residues are shaded blue and non-polar
residues are shaded yellow, highlighting the conserved C-terminal hydrophobic
motif outlined in black. The conserved cysteine is shaded in gray, and note that
the S. intermedius AIP contains a serine instead of a cysteine that forms a lactone
instead of a thiolactone. This figure is adapted from Wright et al. (55).
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The mechanism of intergroup agr interference is thought to be competitive
antagonism of the AgrC receptor (41). The relaxed AIP sequence requirements
for antagonism suggest that an AIP binding event is sufficient for blocking
activation of AgrC by a cognate AIP and that AgrC activation requires an
additional, specific agonistic interaction. Wash-out and order of addition
experiments indicated that both agonists and antagonists bind AgrC in a
reversible

manner

(41),

consistent

with

competitive

antagonism

and

contradictory to an earlier model involving receptor acylation by the thioestercontaining AIP (19). To further test this idea, AgrC was treated with various
concentrations of antagonistic AIPs to construct a series of AgrC activation
curves (41). As expected for simple competitive antagonism, the curves shifted in
dextral fashion in the presence of increasing antagonist. However, the derived
Schild slopes were significantly less than unity, the value expected for simple
antagonism. Moreover, inverse agonism was recently observed in constitutively
active AgrC mutants (42), raising the possibility that some non-cognate AIPs
induce and/or stabilize an inactive receptor conformation. Ultimately, a direct
AgrC-AIP binding assay will be needed to fully understand the molecular
pharmacology of agonism and antagonism of the receptor.
1.2.3 AIP Recognition by the Receptor Histidine Kinase, AgrC
AgrC is a member of the small, unique HPK10 family of quorum sensing
receptors in Gram-positive bacteria (Figure 7A) (56). These receptors have
polytopic

transmembrane

sensor

domains

and

distinctive

sequences

surrounding the phosphorylation site histidine and catalytically important N-box
and G-box residues. They also lack a D-box motif, typically involved in
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Figure 7. Histidine Protein Kinase Family 10 Alignment and AgrC Domain
Structure. (A) Alignment of three conserved motifs among six HPK10 family
members and two distantly related HPKs of Gram negative bacteria (56).
Residues that are identical among all HPKs shown are shaded yellow and other
conserved motifs are shaded turquoise. The H-box histidine is the site of
phosphorylation, and the N-box and G-box asparagine and glycines are
important for ATP binding. (B) The domain structure of AgrC, including the
locations of the residues shaded yellow in (A). The hash marks indicate a
predicted coiled-coil. The transmembrane topology of AgrC-I is shown (57),
along with three residues important for recognition of AIP-I (58).
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nucleotide binding, and a coiled-coil HAMP (histidine kinase, adenylyl cyclase,
MCP, and phosphotase) domain, which links the sensor and HK domains and
often plays roles in dimerization and signal transduction in other HPKs (59-61).
AgrC contains a putative coiled-coil in the DHp subdomain (Figure 7B), which
may mediate homodimerization; but at the outset of this study, there was no
definitive proof that AgrC is a homodimer either before or after AIP binding. It is
generally believed that AIP binding results in trans-autophosphorylation of an
AgrC dimer and subsequent phosphorylation of AgrA on a conserved aspartate
residue (33, 57). However, experimental evidence for this model was missing
prior to this work, and the question of how AgrC transduces the extracellular
AIP signal to trigger intracellular kinase activation was open.
While both activation and inhibition determinants of the AIPs have been
extensively studied as described in Section 1.2.2, work to understand the
corresponding specificity determinants in the AgrC receptors has just recently
begun. In the first study to probe this question, AgrC sensor domain chimeras
were constructed (55). Segments of the proximal and distal halves of the sensor
domains

were

switched

among

different

receptor

specificity

types,

corresponding to different S. aureus agr groups. These intradomain chimeras
were then tested for activation and inhibition specificity against synthetic AIPs
and AIP analogues. This approach facilitated localization of the region of
receptor–ligand specificity and uncovered a key hydrophobic AgrC–AIP
recognition, which may explain the mechanism of staphylococcal cross-group
interference.
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The AgrC sensor domain comprises the first ~205 amino acids out of 430
and contains six predicted transmembrane domains (Figure 7, 8) (57). Although
the sensor domains of the four AgrC receptors are divergent, the transmembrane
topology appears to be highly conserved, as judged by the spacing of the
putative hydrophobic -helices (55). Residues 86-93 within the third
transmembrane domain are identical in AgrC-I, III, & IV and were chosen as the
junction site for the AgrC chimeras (Figure 8). The resulting constructs were
transduced into a -lactamase reporter strain (52) in order to analyze their
activities. In general, the functionality of each chimera was proportional to the
degree of sequence conservation between the two contributing receptors. AgrC-I
& IV sensor domains share 87% sequence identity, and both AgrC-I::IV (Nterminal portion of AgrC-I fused to C-terminal portion of AgrC-IV sensor
domain) and AgrC-IV::I were functional. Chimeras involving AgrC-III (~54%
sequence identity with AgrC-I & IV) were functional but had unpredictable
activities. Finally, chimeras involving AgrC-II, the receptor of the most divergent
agr group, were not functional. Attempts to detect AgrC and the chimeras by
western blot were unsuccessful in this study; thus, it was unclear whether the
lack of function was due to poor expression or the inability to respond to the AIP
agonist. The activities of the six functional chimeras, AgrC-I::IV, IV::I, I::III, III::I,
III::IV, and IV::III, were tested (55).
The chimeras of the group I & IV receptors were activated by both AIP-I &
IV and inhibited by AIP-II and truncated AIP-II (trAIP-II), in line with the trends
observed with the two native receptors (Table 2). However, AgrC IV::I was
activated much more strongly by AIP-I than AIP-IV; whereas, the opposite was
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Figure 8. AgrC Topology. The red line in the third transmembrane region
represents the chimeric junction used in the study by Wright et al. (55). The
sequence shown is of AgrC-I, and the shaded residues indicate the amino acids
that differ in AgrC-IV. Five key residues for group I/IV specificity are
highlighted (58), and the corresponding amino acids of AgrC-IV are shown. This
figure is adapted from Geisinger et al. (58), and the topology shown is based on
Lina et al. (57).
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Table 2. Activities of AIPs and AIP Derivatives against AgrC Sensor Domain
Chimeras.
AIP
Derivative
AIP-I

AgrCI::IV

AgrCAgrCAgrCIV::I
III::I
III::IV
Activation EC50 (nM), (95% CI)
++
+
30,
1700,
(15-45)
(1500-1900)
-

AIP-II

+
1220,
(1050-1410)
-

AIP-III

-

-

-

-

AIP-IV

-

+
340,
(290-410)
-

AIP-I/IV 5A
trAIP-II

-

++
120,
(110-125)
+
440,
(350-530)
-

-

AIP-I/IV 5N

++
6,
(5-7)
-

-

-

AIP-II N3A
AIP-II L8A
AIP-II F9A
AIP-II F9Nal
Linear AIP-I

nt
nt
nt
nt
nt

nt
nt
nt
nt
nt

nt
nt
nt
nt
nt

nt
nt
nt
nt
nt

Linear AIP-II

-

AIP-I
AIP-II
AIP-III
AIP-IV
AIP-I/IV 5N
trAIP-II
AIP-II L8A
AIP-II F9A
Linear AIP-II

nt
+
nt
+
+
nt
nt
-

nt
nt
nt
Inhibition IC50 (nM), (95% CI)
nt
nt
+
+
+
+
+
+
+
nt
+
nt
nt
+
+
+
+
+
nt
nt
nt
nt
nt
nt
nt
nt
nt

AgrCI::III

AgrCIV::III

+

++

+
3100
++
48
++

+
640
++
4
++

++

++

++
++
160
++
+
3100
-

++
++
50
++
+
6700
+

nt
nt
nt
nt
nt
nt
nt
nt
-

nt
nt
nt
nt
nt
nt
nt

Chimeras are notated as AgrC-X::Y, referring to the agr group identities of the Nterminal (X) and C-terminal (Y) portions of the sensor domain. Precise EC50 and
IC50 values and 95% confidence intervals are given if known. Number of plus (+)
symbols indicates the approximate activity. + = EC50 or IC50 value <200 nM. ++ =
EC50 or IC50 value >200 nM. - = no detectable activity. nt = not tested.
24

true for AgrC-I::IV (Table 2). As previously suggested by Lina et al. (57), this
result indicates that the major determinant of AIP recognition is in the distal, Cterminal region of the sensor, at least within agr groups I & IV. The
corresponding moiety within the AIP that makes the defining group-specific
contact with the AgrC distal region is the residue at position five within the
thiolactone ring, as it is the only difference between AIP-I & IV (Figure 3).
Furthermore, an AIP derivative with asparagine at this position (AIP-I/IV 5N)
that activates AgrC-I but inhibits AgrC-IV (52), has precisely the same effects
with the AgrC-IV::I & I::IV chimeras, activating the former and inhibiting the
latter (Table 2). Nonetheless, the N-terminal, proximal region of AgrC also
contributes a significant role in receptor specificity, as AIP-I was much more
potent against AgrC-I::IV than against the native AgrC-IV (Table 1 & 2).
The sensor domain chimeras in which the proximal region was derived
from AgrC-III followed the trend of the AgrC-I/IV chimeras but were much less
sensitive to activation by the AIPs. For example, AgrC-III::I was activated by
AIP-I at concentrations two orders of magnitude higher than that required to
activate AgrC-IV::I and was not cross-activated by AIP-IV (Table 2). Similarly,
AgrC-III::IV was activated by AIP-IV but not AIP-I or III. In fact, AIP-IV and
AIP-I/IV 5N inhibited AgrC-III::I, and AIP-I inhibited AgrC-III::IV, adding
support to the idea that the proximal region of the AgrC sensor plays a role in
specificity, albeit inferior to that of the distal region.
The results with the final AgrC-I::III & IV::III chimeras were quite
surprising. Akin to the behavior of the chimeras described above, they were
preferentially responsive to AIP-III; however, both of these chimeras were also
strongly activated by many other AIP analogs (Table 2). These included several
25

potent inhibitors of AgrC-III, such as AIP-I, II, & IV (19, 37), and inhibitors of all
four agr groups, such as AIP-I D5A and trAIP-II (40, 52). Even linear AIP-I & II,
which are generally inert against AgrC (37, 53), were found to weakly activate
one or both of these chimeras. Moreover, no AIP or AIP derivative tested could
inhibit activation of either receptor. Whereas the requirements for activation are
typically much stricter than those for inhibition, AgrC-I::III & IV::III seemed
poised for activation by any ligand that can bind. These chimeras appeared to no
longer be regulated by putative group-specific determinants that are presumed
to be responsible for activation of native AgrC receptors.
One commonality among all the AIPs and AIP derivatives that activated
AgrC-I::III & IV::III and, in fact, among all known AIPs (Figure 6) is the presence
of two hydrophobic, usually bulky amino acids at the C-terminus. With the
exception of the central cysteine, no other positions in the AIPs are so strongly
conserved. Replacement of the corresponding residues with alanine in the AIP-II
derivatives L8A & F9A abolished agonism and antagonism of AgrC by these
peptides (Table 1) (19). These observations, along with the results involving
AgrC-I::III & IV::III led to the hypothesis that an AIP agonist makes two types of
interactions with the receptor: a general hydrophobic interaction mediated by at
least one of the C-terminal nonpolar residues in the peptide; and a sequencespecific contact that results in activation via change(s) in receptor conformation.
According to this premise, a distortion within the AgrC-I::III & IV::III chimeras
bypasses the need for specific contacts, and all that is required for activation is
the ability to bind. A major prediction of this hypothesis is that removal of one or
both bulky, hydrophobic C-terminal side chains will eliminate binding and thus
eliminate activation of the AgrC-I::III & IV::III chimeras.
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To test this prediction, AgrC-I::III & IV::III were treated with AIP-II L8A &
F9A and found to be completely insensitive to these peptides (Figure 9 and
Table 2). In contrast, AIP-II N3A and AIP-I D5A, which contain alanine
substitutions at sites crucial for activation of native AgrCs and inhibit all four S.
aureus agr groups (41, 52), were strong activators of AgrC-I::III & IV::III. This
finding suggests that an alanine replacement at either of the C-terminal positions
in the hydrophobic patch of the AIP causes a significant defect on receptor
binding. However, an AIP-II variant with naphthylalanine at position nine,
designed to increase the C-terminal hydrophobicity and therefore the potency of
AIP-II failed to activate the native and chimeric AgrC receptors, suggesting that a
steric constraint superseded the hydrophobic interaction in this case.
Based on the finding that the determinants for specific recognition of AIPI vs. IV are localized to the C-terminal region of the AgrC sensor domain,
Geisinger et al. (58) set out to find the individual amino acids responsible for the
ligand specificity. Of the 27 amino acid differences between the AgrC-I & IV
sensor domains, only seven are located in the C-terminal region of interest
(Figure 8). According to a topological model of AgrC (57), five of those seven
residues are located in or near one extracellular loop, while the other two are
facing the cytoplasm. Thus, the five residues of interest in AgrC-IV were
systematically replaced with the corresponding amino acids in AgrC-I, and
reciprocal mutations were made in AgrC-I. The activities of the resulting
constructs showed that the main specificity determinants between AgrC-I & IV
are indeed the five divergent residues in the second extracellular loop.
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Figure 9. Dose-response Curves for AIP-II and Derivatives against AgrCIV::III. Data are presented as percent maximal activation of the receptor by AIPII expressed as Vmax -lactamase activity. All data points represent two to three
replicates, and error bars represent standard error measurements (SEM). Nal =
naphthylalanine.
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Initially, all five residues (100, 101, 104, 107, and 116) were swapped
between AgrC-I & IV, and the activities of the resulting constructs, AgrC-IV (100116 C-I) and AgrC-I (100-116 C-IV), were quantified in a -lactamase reporter
assay (52). The mutations switched the specificities of both receptors almost
completely (Table 3), indicating that the determinants of AgrC specificity for
groups I & IV indeed lie in the central extracellular loop (Figure 8). AgrC-IV (100116 C-I) was more sensitive to AIP-I than AIP-IV with EC50 values matching
those for wild type (WT) AgrC-I and vice versa, the only exception being that
AgrC-I (100-116 C-IV) was more sensitive to AIP-I than WT AgrC-IV.
To assess the individual contributions of each residue, many AgrC-I & IV
mutants were constructed in which one to four of the residues of interest were
switched between the two receptors. This analysis facilitated further narrowing
of the major specificity determinants to Thr/Val104, Ser/Val107, and Ser/Ile116,
although the specificity switch exhibited by these three changes was not quite as
robust as when all five residues were swapped (Table 3).
Examination of the key specificity determinants of the AIPs and AgrCs
revealed an interesting trend. Position five of AIP-I (Asp) and positions 104, 107,
and 116 in AgrC-I (Thr, Ser, Ser) are all polar amino acids, while the
corresponding positions in AIP-IV (Tyr) and AgrC-IV (Val, Val, Ile) are all
nonpolar (Figure 8). Thus, Geisinger et al. (58) hypothesized that polar versus
nonpolar interactions drive specificity in this case. Position five of AIP-I/IV was
replaced with different polar and nonpolar residues to test whether these AIP
derivatives also followed the observed trend. Whereas the activity of AIP-I/IV
5N was consistent with the hypothesis and activated WT AgrC-I but not AgrCIV; surprisingly, AIP-I/IV 5L also activated AgrC-I but not AgrC-IV (Table 3). In
29

Table 3. Activities of AgrC-I/IV Mutants.
AgrC Variant

AIP-I

AIP-IV

AIP-I/IV
5N
Activation EC50 (nM), (95% CI)
AgrC-I
11,
100,
85,
(9-12)
(86-130)
(61-120)
AgrC-IV
1500,
16,
–
(1000-2100)
(13-20)
AgrC-IV (100-116 C-I)
25,
140,
180,
(22-28)
(130-160)
(160-200)
AgrC-I (100-116 CI-IV)
44,
7,
nt
(34-58)
(6-8)
AgrC-IV (104, 107, 116 C-I)
37,
45,
130,
(31-43)
(38-55)
(110-160)
AgrC-I (104, 107, 116 C-IV)
520,
290,
nt
(440-620)
(250-330)
AgrC-IV (107, 116 C-I)
50,
56,
150,
(40-63)
(45-71)
(130-170)
AgrC-I (107, 116 C-IV)
450,
100,
nt
(330-610)
(85-120)
AgrC-IV (100, 101 C-I)
1100,
620,
–
(1000-1300)
(560-670)
AgrC-I (100, 101 C-IV)
8,
15,
nt
(7-9)
(12-18)

AIP-I/IV
5L
20,
(15-28)
–
290,
(170-490)
nt
19,
(17-22)
nt
29,
(23-36)
nt
nt
nt

95% CI = 95% confidence interval. – = no activity up to the highest concentration
tested, > 10 μM. nt = not tested.
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fact, AIP-I/IV 5F is the only position five substitution that has been shown to
strongly activate AgrC-IV (Table 1) (52). These results suggest that the ligand
specificity of AgrC-I is broader than that of AgrC-IV, and further work will be
required to determine the exact nature of the interaction of position five of AIPIV with AgrC-IV.
In a subsequent, similar study, Jensen et al. (62) swapped the five key
residues in the middle extracellular loop of AgrC-I & IV plus residues in or near
the first extracellular loop (Figure 8). When residues 35, 38, 39, 41, 42, 44, and 45
of AgrC-IV were mutated to the corresponding amino acids of AgrC-I, the
potency of AIP-IV dropped more than two orders of magnitude, and the
reciprocal substitutions in AgrC-I abolished the ability of AIP-I to activate it.
However, inhibition did not appear to be affected by the mutations, as AIPI/IV 5A was a potent inhibitor of both mutant receptors. This result suggests that
the loop one residues contribute important determinants for activation,
consistent with the earlier findings using AgrC sensor domain chimeras (55). An
alternative possibility is that the seven replacements in AgrC result in poor
expression that explains the weakened activation relative to WT receptors.
1.2.4 The AgrA Response Regulator
The AgrA RR contains 238 amino acids split into two main domains, as
predicted

by

homology

modeling

(Figure

10A)

(63).

The

putative

phosphorylation site aspartate is in the N-terminal CheY-like receiver domain,
which presumably modulates DNA binding by the C-terminal LytTR domain.
The majority of RRs bind DNA via helix-turn-helix or winged helix motifs, but
RRs of the LytTR family contain a novel fold (63, 64). Recently, a crystal structure
of residues 137-238 of AgrA in complex with a 15-base pair DNA duplex showed
31




 

 





 





 









Figure 10. AgrA Domain Structure and LytTR Domain Crystal Structure. (A)
AgrA domain structure. The N-terminal CheY-like receiver domain is
phosphorylated by AgrC, causing an activating conformational change in the Cterminal DNA binding LytTR domain. The approximate position of the
phosphorylation site aspartate based on sequence alignment is shown. (B) The
structure of the LytTR domain in complex with DNA was recently solved (64),
demonstrating that AgrA has a novel ten-stranded  fold arranged into three
antiparallel  sheets. Three key residues that interact with DNA are indicated.
The  strands are colored blue, and the helices are colored red.
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that it contains a novel 10-stranded  fold (Figure 10B) (64). His169 and Arg233
make base-specific contacts with DNA, and subsequent mutagenesis confirmed
they are essential for DNA binding. However, the structure did not provide an
explanation for the previous observation that the appropriate length of the Cterminus is essential for activity (65). A frameshift mutation in agrA resulting in a
C-terminal amino acid sequence of KKNIIR instead of KKI is the cause of a delay
in RNAIII production and lack of hemolytic activity in S. aureus strain RN4220.
Addition of acetyl phosphate promotes homodimerization of AgrA, suggesting
that the phosphorylated dimer is the active species (33). Thus, the AgrA Cterminus may be important for homodimerization, stability, or other protein–
protein interactions (33, 64). Additionally, the conformational changes associated
with phosphorylation and how they regulate the LytTR domain as well as the
recognition of and interaction with AgrC by AgrA are yet to be characterized.
1.2.4 Output of the agr Response
The primary effector molecule of the agr response, RNAIII, acts as both a
messenger and antisense RNA to carry out multiple functions (13). The 514
nucleotide transcript contains fourteen hairpin stem loops (Figure 11), including
three C-rich hairpins, which is unusual for an AT-rich organism such as S. aureus
(66). Nucleotides 85-165 encode the exotoxin -hemolysin, and 300 nucleotides
downstream, the 3’-end regulates its expression through a poorly understood
mechanism (66, 67). The RNAIII 5’-region directly up-regulates hla (-hemolysin)
by annealing to the mRNA translation initiation region, causing a conformational
change that unmasks the ribosomal binding site (68). Conversely, the RNAIII 3’end binds and occludes the ribosomal binding site of mRNAs targeted for down-
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Figure 11. RNAIII Structure. The fourteen hairpin loops are numbered, as are
the nucleotides. This figure is taken from Huntzinger et al., and the line drawn
through the image pertains to experiments completed in that study (70).
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regulation, including several cell surface-associated virulence factors and the
pleiotropic transcription factor rot (26, 69, 70). The expression of other virulence
genes modulated by agr may also be directly mediated by RNAIII, by regulation
of transcription factors in addition to Rot, or by undiscovered targets of
AgrA (35).
Until recently, the regulation of virulence via induction of transcription at
the agr P2 and P3 promoters by AgrA was the only known output of the agr
response. However, Queck et al. observed that genes related to carbohydrate and
amino acid metabolism and staphyloxanthin pigment biosynthesis are downregulated upon agr activation by a mechanism they were unable to
determine (35). The effect was observed even when RNAIII was deleted, and
AgrA is unlikely to be involved since the target genes lack consensus AgrA
binding sequences (35). Furthermore, phenol-soluble modulins (PSMs), virulence
factors prevalent in community-acquired strains of MRSA (as opposed to
hospital-acquired strains) (36), were found to be up-regulated by the agr
response independent of RNAIII expression (35). In this case, the promoter
regions contain AgrA consensus binding sequences, and AgrA was shown to
bind and activate transcription of PSMs.
1.3 Goals of this Work
The overall goal of this work was to elucidate molecular mechanisms of
AgrC signaling in order to further develop the understanding of the polytopic
peptide-sensing HPK10 receptor family and of virulence regulation in S. aureus.
As described above, the requirements for inhibition of AgrC are significantly less
stringent than those for activation, and while many AIP derivatives lose the
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ability to activate, almost all of those tested maintain inhibition. Hence, one aim
was to determine the minimal determinants within AIPs for inhibition of AgrC.
This endeavor necessitated a streamlined AIP synthesis; thus, the development
of a convenient method for the synthesis of Fmoc-based thioester peptides was
an additional goal. While those efforts were fruitful, the major focus of this work
was to elucidate the mechanism of AIP-induced activation of AgrC. The
paradigm for HPK signaling is that they function as dimers and undergo transautophosphorylation (32, 71), but it was not known whether AgrC or other
HPK10 receptors follow this model. The first step was to resolve this uncertainty,
and if the hypothesis that AgrC follows this precedence is correct, a further aim
was to determine whether or not AIP binding affects oligomerization. A related
goal was to determine the AIP–AgrC stoichiometry. Finally, perhaps the most
intriguing question regarding the mechanism of AgrC signaling is how
recognition of the AIP signal is transduced through the receptor to activate the
kinase domain, and the last aim of this work was to shed light on that issue.
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Chapter 2: Inhibitors of AgrC Prepared by Fmoc-Based Peptide Synthesis
2.1 Introduction
Despite the fact that many AIP derivatives have been synthesized and
characterized (19, 40, 41, 52-54) (Table 1), linear AIPs and those missing bulky
hydrophobic side chains at the C-terminus are the only variants found thus far to
lack inhibitory activity (19, 55). Even substantial modifications, which
dramatically reduce the ability to activate, compromise inhibitory potency only
slightly if at all. For example, removal of the four tail residues of AIP-II, nearly
half of its nine amino acids, has little effect on inhibition of AgrC-I, -III, & -IV,
and converts the peptide from an agonist of AgrC-II to an antagonist (40). These
observations raised the question of how much further the AIP structure can be
minimized before losing the ability to inhibit AgrC, and the truncated AIP-II
(trAIP-II) pentapeptide provided an ideal starting point. In order to define the
minimal AIP pharmacophore and discover the minimal determinants for AgrC
inhibition, ten trAIP-II analogues were synthesized. The peptide backbone, side
chains, thiolactone linkage, and N-terminus were modified to systematically
probe each structural element of the molecule. To rapidly synthesize these
peptides in parallel, an Fmoc-based method was preferred to avoid a bottleneck
at the cleavage step, which requires use of anhydrous HF in Boc-based methods.
The synthesis of Fmoc-based thioester peptides has been a longstanding problem
due to the incompatibility of thioesters with basic Fmoc deprotection conditions.
While many methods have been reported, none have gained widespread use
owing to various drawbacks, including lack of generality and low yields (72, 73).
Therefore, a new Fmoc-based AIP synthesis was developed for this study that is
also generally useful for the preparation of linear thioester peptides.
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2.2 A New Synthetic Method for Thioester Peptides and AIPs via Fmoc-SPPS
An attractive starting point from which to develop a more convenient
method for the generation of thioester peptides by Fmoc-SPPS was the latent
thioester-linker work of Botti et al. (74) and Warren et al. (75). In these methods,
C-terminal thioesters are masked as esters during amino acid coupling steps then
revealed via an intramolecular O to S acyl shift. Whereas the Warren
methodology requires a solution-phase coupling step with a partially protected
peptide, the simpler Botti methodology seemed more amenable to adaptation for
use in an AIP synthesis. In this approach, Fmoc-cysteine (t-butylthio)-OH is first
coupled to PEGA resin, followed by -amino diazotization and subsequent
hydrolysis under aqueous conditions to afford an -hydroxy cysteine resin
(Figure 12A). After chain elongation and cleavage from the resin, reduction of the
cysteine side-chain disulfide leads to an O to S acyl shift, resulting in -thioester
formation. The authors chose thiophenol as the reducing agent (Figure 12B), as
the main motivation of the work was to generate thioesters for use in native
chemical ligation (76). However, TCEP was used for AIP synthesis (Figure 12D)
to avoid reduction of the AIP thiolactone. AIPs were successfully generated with
this slight adaptation of the Botti method, but the isolated yields were very low.
This result highlights the main drawback of this method: the linker is
synthesized on resin, consequently limiting the resin options to those that have
good swelling properties in water that often result in low yields. To overcome
this limitation, a solution-phase synthesis of 2-(t-butyl-dimethyl-silanyloxy)-3-tbutyldisulfanyl-propionic acid (5) (Figure 12C) was designed to make a version
of the linker that can be coupled to any resin using standard approaches.
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Figure 12. Synthetic Routes for Fmoc-Based Thioester Peptides. (A) Synthetic
scheme of Botti et al. (74). Diazotization of the -amine on PEGA resin (orange)
in aqueous conditions yields an -hydroxyl. (B) Thiophenol reduces the linker
disulfide, and the resulting acyl shift reveals the thioester. (C) New Fmoc-based
AIP synthesis. The -hydroxy cysteine linker (5) is made from thioglycerol and
coupled to Rink resin (blue) via standard SPPS. (D) Addition of TCEP results in
one-pot reduction, O to S acyl shift, and transthioesterificaiton, yielding the AIP.
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Initial efforts to generate -hydroxy-cysteine-based linkers in solution
from t-butylthiol protected L-cysteine proved to be unsatisfactory, primarily due
to the poor yields associated with the diazotization/hydrolysis step. Therefore,
we adopted an alternate route in which the linker was generated in five steps
from commercially available thioglycerol, with an overall yield of 31%. As shown
in Figure 12C, the thiol group was first protected as the t-butyl disulfide to give a
1,2-diol (1). Attempts to selectively oxidize the primary alcohol directly to the
carboxylic acid using TEMPO were unsuccessful. Instead, protection of both
alcohols with t-butyl-dimethyl silanyloxy (TBS) groups, followed by selective
removal of the primary TBS group facilitated selective oxidation to the acid in
two steps, using Dess-Martin periodinane and subsequent treatment with
sodium chlorite.
An updated version of the synthesis was developed in collaboration with
Mette Jensen, Maya Bar-Dagan, and Matt Pratt since the initial publication of this
method (77). The new steps avoid the requirement of addition of a large excess of
the extremely malodorous t-butylthiol to form the disulfide protecting group
(Figure 12C and Materials and Methods). Instead, t-butylthiol is first activated
for disulfide exchange by conjugation to 2,2’-dithiodipyridine, necessitating only
1.1 equivalents of t-butylthiol relative to thioglycerol as opposed to ten or more.
trAIP-II was chosen as the first AIP synthesized using the new linker, as it
is a well characterized peptide (40) and would be useful for the subsequent study
of minimal inhibitory AIP determinants. The -hydroxy cysteine linker was first
coupled onto Rink-amide polystyrene resin with HBTU and DIEA (Figure 12B).
Following a capping procedure and on-resin removal of the TBS group with
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TBAF, the C-terminal phenylalanine was double coupled to the linker using
HBTU in the presence of catalytic DMAP. HPLC–MS analysis of the cleaved
amino-acylated resin indicated that this loading procedure was highly efficient,
as no free linker was observed in the crude mixture (data not shown). Peptide
chain assembly was then performed using standard Fmoc-SPPS protocols, and
the peptide was cleaved from the resin with TFA and water and TIS as
scavengers. HPLC–MS analysis of the crude cleavage mixture revealed the
presence of two closely eluting peaks, both with the mass expected for the
desired linear peptide–linker product. The first panel in Figure 13A shows the
crude cleavage mixture obtained for the linear precursor to trAIP-II. The two
products were presumed to correspond to the two expected diastereomers that
result from use of the racemic linker. No attempts were made to purify these
putative stereoisomers since the linker would eventually be cleaved off during
the cyclization reaction. Indeed, incubation of crude, linear trAIP-II in an
aqueous buffer containing the reducing agent TCEP resulted in the collapse of
the two peaks into a single new peak with a mass consistent with the desired
thiolactone peptide (Figure 13). Homonuclear 1H 2-D NMR analysis confirmed
that the reaction product was trAIP-II (6), and the 2-D 1H TOSCY spectrum was
identical to an authentic sample of trAIP-II prepared by the Boc-SPPS route
(Figure 5) (see Appendix for chemical shift assignments).
The macrocyclization reaction was found to be the most efficient between
pH 6.6-6.8, taking approximately 1-2 h to reach completion. If the pH was below
6.6, the linear, reduced peptide intermediate predominated and proceeded very
slowly to product, presumably due to a slow rate of O to S acyl shift. At higher
pH values, hydrolysis of the thioester to give the -carboxy-peptide became
41




 

 













 



 



 



























 













 










 


















































































Figure 13. HPLC–MS Analysis of the Macrocyclization Reaction. (A) HPLC
chromatograms of the crude reaction mixture at the time points indicated. S. M.
is the protected, linear trAIP-II starting material. I. is the reduced (deprotected)
intermediate(s), and P. is the product, trAIP-II. (B) Mass spectra of the
corresponding peaks.
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increasingly problematic. Within the appropriate pH range, analysis of the
reaction mixture after five minutes revealed the presence of several intermediates
with a mass consistent with the fully reduced version of linear trAIP-II
(Figure 13). At least one of these intermediates was presumed to correspond to
the linear -thioester generated in situ following the O to S acyl shift, although it
is likely a minor component due to the greater stability of oxyesters over
thioesters (78). Furthermore, the linear -thioester peptide is an obligatory
intermediate in the proposed cyclization mechanism (Figure 14B), leading to the
final transthioesterification step, which acts as a thermodynamic sink in the
reaction. Given that acyl transfer from a hydroxyl group to a thiol group is
highly unfavorable, the O to S acyl shift is predicted to occur via the entropically
preferred five-membered ring as opposed to attack by a distal thiol. To directly
test whether or not the N-terminal cysteine could attack the oxyester, a trAIP-II
derivative with an unprotected N-terminal thiol group and protected linker thiol
group was subjected to the cyclization conditions without TCEP. Consistent with
the proposed mechanism, cyclization of this peptide was not observed; however,
upon the addition of TCEP, the peptide cyclized efficiently (Figure 14). Thus, the
N-terminal thiol attacks only the thioester that is generated by deprotection of
the linker and subsequent acyl shift.
2.3 Minimal Determinants for AIP Inhibition of AgrC
The strategy used to elucidate the minimal determinants of AgrC
inhibition was to systematically perturb each structural aspect of the already
partially minimized trAIP-II derivative of AIP-II. Guided by previous SAR
carried out with AIP-II (19, 40), ten AIP-II analogues based on the trAIP-II
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Figure 14. Testing the Proposed Mechanism of Macrocyclization. (A) Two
possible products upon treatment of the partially unprotected peptide with the
macrocyclization buffer minus TCEP. The thiolactone was not observed, only
disulfide formation. (B) HPLC chromatograms and corresponding mass spectra
of the reaction. The starting material (S. M.) was nearly completely consumed,
and the product (P.) was the cyclic disulfide, not the thiolactone.
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scaffold were synthesized (Figure 15) to test the importance of the peptide
backbone, side chains, thiolactone linkage, and N-terminus for inhibition. In
order to compare trends for both cognate and non-cognate inhibition, the
activities of all analogues were tested against AgrC-II and AgrC-I, respectively.
This SAR analysis led to the identification of a minimal pharmacophore structure
with a reduced peptidic character that retains antagonism of AgrC.
2.3.1 Design and Synthesis of trAIP-II Analogues
Previously, alanine scanning of full-length AIP-II showed that the two
serine hydroxyl groups of residues six and seven are not necessary for biological
activity (Table 1) (19). Given this observation, the serines were replaced with
glycines either individually or in combination in the first three trAIP-II analogues
(Figure 15). The same alanine scanning study showed that the two C-terminal
hydrophobic side chains are required for both activation and inhibition (19).
Moreover, the inability of AIP-II L8A and AIP-II F9A to activate the promiscuous
AgrC-I::III & IV::III sensor domain chimeras (55) confirmed that the conserved
hydrophobicity of the two C-terminal residues (Figure 6) is required for
biological activity. Therefore, the leucine and phenylalanine side chains were not
perturbed in this study. Next, each amide in the macrocycle was N-methylated to
probe interactions involving the AIP backbone, which had yet to be evaluated in
any AIP. To test whether these side-chain and backbone modifications could be
combined, the serines were completely removed and replaced with a methylene
linker derived from 5-aminopentanoic acid in peptide 14 (Figure 15).
Additionally, previous SAR studies on full-length AIP-II revealed that the
thiolactone linkage is a critical determinant in receptor activation, but,
interestingly, not inhibition (19). For example, a lactam analogue of AIP-II is a
45
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Figure 15. Structures of trAIP-II and Derivatives Synthesized for Study of the
Minimal Inhibitory AIP Pharmacophore. The portions of each molecule colored
red indicate the residue(s) modified relative to trAIP-II.
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very poor agonist but potent antagonist of the agr response (19, 52). In contrast,
the trAIP-II lactam was found to be a very poor inhibitor of AgrC-II (79). To
confirm this result and to determine whether non-cognate inhibition is
diminished to the same extent as cognate inhibition, the lactam (15) was
constructed. Lastly, the acetylated -amino group of the N-terminal cysteine was
removed to make 16 (Figure 15), allowing determination of any role this vestige
of the native AIP tail may play in the inhibitory activity of the peptide.
All but one of the desired thiolactone peptides was generated in good
yield and purity using the general procedure shown in Figure 12B. The sole
exception was N-MeF (13), which contains N-methylphenylalanine at the Cterminus (Figure 15). Attempts to synthesize the linear precursor to this peptide
by Fmoc-SPPS on the -hydroxy cysteine linker led to low yields, and the crude
mixture contained significant amounts of deletion products lacking the last two
residues,

Leu

and

N-Me-Phe.

These

problems

were

attributed

to

diketopiperazine (DKP) formation resulting from the presence of the tertiary
amide at N-Me-Phe, a problem that is well known for C-terminal proline
containing peptides prepared by Fmoc-SPPS (80) and that has been reported as a
side reaction in the synthesis of N-methylated peptides (81). Consequently, the thioester precursor to peptide N-MeF was generated using the Boc-SPPS strategy
(Figure 5) employing in situ neutralization chemistry (82) during the chain
assembly to suppress DKP formation. Finally, the chain elongation for the lactam
analogue (15) was completed using standard Fmoc-SPPS, as this peptide does
not contain a thioester. To form the lactam, the cysteine was replaced with
diaminopropanoic acid, and the serines were deprotected with HF following
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cyclization of the partially protected linear peptide in solution (Materials and
Methods) (19). Characterization and analysis of the purity of all AIP analogues
was completed by HPLC, MS, and NMR (Table 4 and Appendix).
2.3.2 Structure–Activity Relationships of trAIP-II
Having obtained all eleven truncated AIP-II analogues, a cell-based
reporter assay was used to determine the inhibitory activities of each peptide
(52). S. aureus cultures of strains that cannot produce AIPs but contain the AgrC–
AgrA TCS cassette and -lactamase driven by the agr-dependent P3 promoter
were treated with the AIP analogues in the presence of the cognate AIP agonist
at 125 nM, a concentration above the EC90 (19, 52). The extent of agr activation
was determined by measuring -lactamase activity via a colorimetric readout. To
test both cognate and non-cognate agr inhibition by the trAIP-II analogues, group
II & I reporter cell lines RN9372 and RN9222 (Materials and Methods) were used,
respectively. The resulting dose-response curves and IC50 values against cognate
(AgrC-II) and non-cognate (AgrC-I) receptors are shown in Figure 16 and Table
4. Importantly, the IC50 values for trAIP-II prepared by the new Fmoc-SPPS route
were in good agreement with those previously determined for this peptide (40).
There are two interesting trends within the activity data summarized in
Table 4. First, the overall rank order of the peptides, in terms of their inhibitory
activities, is remarkably similar for the cognate and non-cognate agr groups.
Second, all of the peptides that exhibited measurable inhibitory activity are more
potent antagonists of the non-cognate AgrC receptor than of the cognate
receptor. Furthermore, this difference in inhibitory activities against the two
receptors increases significantly for the less potent analogues. This trend is more
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Table 4. Mass Spectrometry and Activity Characterization of trAIP-II and Ten
trAIP-II Analogues.
AIP
Derivative
trAIP-II (Boc)
trAIP-II
(Fmoc) (6)
S2G (7)
S3G (8)
GG (9)
N-MeS2 (10)
N-MeS3 (11)
N-MeL (12)
N-MeF (13)
Meth Link (14)
Lactam (15)
 N-term (16)

Mass
Mass
Expected Observed
(M+H+)
(M+H+)
579.2
579.0
579.2
580.0
549.2
549.2
519.2
593.3
593.3
593.3
593.3
504.2
562.3
522.2

550.7
550.0
520.7
595.0
595.0
595.0
595.0
505.0
564.0
524.0

AgrC-I IC50 (nM),
(95% CI)

AgrC-II IC50 (nM),
(95% CI)

260, (95-695)
90, (78-104)

230, (190-270)
293, (245-350)

189, (151-237)
40, (33-48)
77, (66-89)
639, (534-765)
319, (284-357)
–
–
1141, (799-1630)
1390, (1250-1560)
1680, (1310-2170)

1160, (855-1560)
194, (167-225)
238, (170-334)
7880, (4100-15,200)
1050, (795-1380)
–
–
507,000, (*)
167,000, (*)
47,300, (33,70066,300)

trAIP-II (Boc) is the version of the peptide made by Boc-SPPS (Figure 5) (40), and
trAIP-II (Fmoc) is the version of the peptide made by the Fmoc-based synthesis
described in Section 2.2 (Figure 12C, D). The IC50 values and the corresponding
95% confidence intervals were computed using nonlinear regression analysis
(Materials and Methods). – = no inhibition observed up to the highest
concentrations tested (10-100 μM). (*) = extremely large span of the 95%
confidence interval (>100,000 nM).
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Figure 16. Inhibition Curves for trAIP-II Derivatives Against AgrC-I & II. In all
cases, 125 nM agonist (AIP-I or II) plus varying concentrations of antagonist were
added to reporter cells. The left panels show inhibitory activities against AgrC-I,
and the right panels show activities against AgrC-II. trAIP-II is shown in all
panels as a reference. Data are presented as percent maximal activation of the
receptor by 125 nM agonist, expressed as Vmax -lactamase activity. All data
points represent two to three replicates, and error bars represent SEM.
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clearly seen in Figure 17, which shows a log-log plot of IC50 values. Thus,
antagonism of the non-cognate agr group is much more tolerant to changes in the
AIP structure than is antagonism of the cognate group. For instance, replacement
of the thiolactone with a lactam leads to a modest decrease in the non-cognate
IC50 (~15-fold) relative to the effect of this change on the cognate activity (~500fold). Similarly, replacement of the two serine residues with a methylene linker
resulted in approximately 13-fold and 1700-fold reductions in non-cognate and
cognate activities, respectively.
Modifications to the serine residues were generally well tolerated. Both
the single and the double glycine mutants (7, 8, and 9) exhibited a minimal loss
of activity (<5-fold) or actually increased potency (Table 4). N-methylation of the
serine residues mildly affected inhibition, although cognate inhibition was
somewhat sensitive to N-methylation of Ser2. In contrast, N-methylation of
leucine or phenylalanine resulted in a complete loss of activity, indicating that
the side chains of these amino acids are not the only functionally important
portions of this region of the AIP.
The replacement of the sulfur with an NH in the lactam (15) resulted in a
similar effect on function as replacement of both serines with a methylene linker
(14), as both peptides have IC50 values of approximately 1 μM against AgrC-I and
over 100μM against AgrC-II (Table 4). Thus, although the thiolactone linkage is
not necessary for inhibition by full-length AIP-II (19), it is required for strong
inhibition in the context of the truncated AIP. The relatively weak activity of the
Meth Link peptide (14) cannot be explained by the loss of the serine side chains
in accordance with the activity data for GG (9) (Table 4). It is more likely that the
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Figure 17. IC50 Values of trAIP-II Derivatives Against AgrC-I vs. AgrC-II. All
peptides fall below the y = x (dotted) line, indicative of the fact that all are more
active against AgrC-I than AgrC-II. The plot also depicts the increasing
differences in inhibitory activities as the inhibitory potencies decrease. The error
bars represent 95% confidence intervals.
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complete loss of an amide bond or the increased flexibility introduced by the
methylene linker is responsible for the reduced potency.
Lastly, the removal of the N-terminal amide group caused a dramatic loss
of inhibitory activity against both cognate (~250-fold) and non-cognate (~55-fold)
receptors (Table 4). This result shows that the N-terminal vestige of the exocyclic
“tail” portion of the full-length AIP is in fact important for inhibition.
2.3.3 NMR Analysis of trAIP-II Analogues
To explore a possible correlation between the differential activities of the
trAIP-II analogues and the solution structures of the peptides, full 1H NMR
chemical shifts were made (Appendix). During this effort, the 1H NMR spectra of
N-MeS3 (11) was found to contain twice the number of expected resonances.
Indeed, standard 2-D sequential assignment methods revealed that the sample
contained two species as a 1:1 mixture in DMSO-d6 at 298 K (Figure 18A). There
was no evidence for chemical heterogeneity in this peptide by HPLC–MS
analysis (data not shown). Likewise, the possibility that these extra signals
resulted from epimerization of the C-terminal Phe during coupling to the
secondary hydroxyl of the linker was excluded since the same batch of aminoacylated resin was used for the synthesis of other peptides in the study. Further
analysis of the ROESY spectrum of N-MeS3 revealed the presence of a strong
NOE cross-peak between the two serine alpha protons in one of the species but
not the other (Figure 18B). This cross-peak is consistent with the presence of a cis
amide bond between Ser2 and N-Me-Ser3. Analogous to the prolyl-tertiary
amide, N-methylation is known to increase the propensity for trans-cis
isomerization of an amide bond (83). Two of the other three N-methylated
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Figure 18. ROESY Spectrum of trAIP-II Derivative N-MeS3. (A) Amide region
of the ROESY spectrum is color-coded to identify the two spin systems that
correspond to the FLV (red) and WUDQV (blue) isomers. (B) Alpha region of the
ROESY spectrum is color-coded as in (A) to show the diagnostic NOE between
the two alpha protons of the N-MeS3 cis isomer.
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peptides, N-MeL (12) and N-MeF (13), were also present as two conformers as
indicated by NMR, with the minor conformer comprising only 10-30% of the
total sample population. By analogy with N-MeS3, these conformers almost
certainly stem from cis-trans isomerization of the tertiary amide bond in these
peptides; however, full assignments were not made for the minor, presumably
cis, isomers of N-MeL and N-MeF owing to their low abundance.
The chemical shift assignments of the eleven peptides were used to
calculate a chemical shift index (CSI) value for each one, allowing comparison of
their solution structures. The CSI is the average difference in proton ppm
between the analogue of interest and trAIP-II, including protons directly bonded
to the macrocyclic scaffold, other than those of the modified residue, plus the
exocyclic N-terminal amide proton. The CSI values were then plotted against
relative inhibitory potencies to examine any relationship between differences in
activity and solution structure among the AIP derivatives compared to trAIP-II
(Figure 19). According to this simple analysis, there was no observable trend
between potency and overall chemical shift perturbations. For instance, N-MeL
(12) and N-MeF (13), which have no measurable activity, have CSI values
comparable to S3G (8) and GG (9), which are the most potent AIP analogues.
Similarly, the chemical shifts around the macrocycle in the  N-term peptide (16)
are largely unperturbed compared to trAIP-II, yet this analogue is one of the least
potent antagonists. One interpretation of this data is that the exocyclic and two
C-terminal amides of trAIP-II make specific contacts with the AgrC receptor.
Alternatively, the modifications may prevent the AIP from assuming a bioactive
conformation required for receptor binding.
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Figure 19. Chemical Shift Index Values vs. Inhibitory Potencies. The CSI values
of each AIP analogues are plotted in order of decreasing potency, from left to
right. The order of the N-MeS3 isomers is arbitrary since they were not
separated; and hence, their individual potencies were not determined.
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The largest CSI was observed for the lactam analogue (15) in which only
one atom was replaced. In this case, chemical shift changes propagate around the
entire macrocycle (Figure 19 and Appendix), indicating that this substitution
induces far-reaching changes in the solution structure of the peptide. A similar
structural effect was previously observed upon substitution of the thiolactone
with a lactam in the context of full-length AIP-II (52) and trAIP-II (79). The fulllength AIP-II lactam remains a potent cross-group AgrC antagonist but is an
extremely weak agonist of AgrC-II (19, 52). Thus, although this major structural
perturbation differentially affects inhibition of AgrC-I depending on AIP length,
activity against the cognate AgrC-II is significantly reduced in both contexts.
2.3.4 Conclusions
Two prominent trends surfaced in this study regarding AIP inhibition of
AgrC. First, the overall rank orders of the analogues for inhibition against
cognate (AgrC-II) and non-cognate (AgrC-I) receptors were almost identical,
despite the fact that the sensor domains of AgrC-II & I share only 31% sequence
identity. However, non-cognate antagonism was more resistant to changes in
AIP structure than cognate antagonism. Of the peptides with measurable
inhibitory activity, the IC50 values against AgrC-I varied by no more than ~40fold, whereas the values against AgrC-II varied by over 3 orders of magnitude
(Figure 17 and Table 4). This observation is broadly in line with previous SAR
studies on full-length AIPs, which revealed that cross-group antagonism is more
tolerant to changes in peptide structure than intra-group agonism (52).
Pharmacological studies of trAIP-II suggested that both cognate and non-cognate
antagonism operates through a simple competitive binding mechanism in which
trAIP-II competes with the group-specific AIP agonist for a common binding site
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on the sensor domain of AgrC (41). The SAR data presented here are certainly
consistent with this mechanism, but the details of the cognate and non-cognate
interactions must differ since certain modifications have a more acute effect on
the former interaction than the latter one.
Taken together, these results facilitated identification of the principle
pharmacophore for agr antagonism by trAIP-II (Figure 20). Roughly one half of
the molecule, including the cysteine and two C-terminal hydrophobic residues, is
critical for activity. Conversely, the remainder of the molecule appears to be far
less important and can even be replaced by an alkyl linker without a dramatic
loss of non-cognate agr inhibition. Further study is needed to understand the
basis for inhibition of multiple receptors via so few structural elements.
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Figure 20. The Minimal Inhibitory AIP Pharmacophore. trAIP-II is color-coded
to indicate which portions of the molecule are important for inhibition against
cognate (AgrC-II) and non-cognate (AgrC-I) receptors.
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Chapter 3: Mechanism of Signal Transduction by AgrC (This work was
performed in collaboration with Edward Geisinger.)
3.1 Introduction
Knowledge of the mechanism by which AgrC transduces the AIP signal is
very limited. The importance of particular motifs for ligand recognition and
specificity within the AgrC sensor domain are beginning to be understood (42,
55, 58, 62). In a recent study by Geisinger et al. (42), several constitutively active
AgrC mutants were isolated with single point mutations that mainly localized to
the C-terminal transmembrane helix of the sensor domain and the putative
coiled-coil/dimerization (DHp) subdomain (Figure 7). These intriguing findings
implied that the C-terminal transmembrane helix may move toward the
cytoplasm in a piston-like movement upon activation and that the DHp
subdomain is important for regulation of activity. Mathiesen et al. (84) isolated
constitutive mutants of the L. sakei receptor histidine kinase SppK, another
member of the HPK10 peptide-sensing family. Although the sites of point
mutations found to confer constitutive activity upon SppK were not conserved in
AgrC, they mainly localized to the DHp subdomain. Furthermore, T233I, a
constitutive mutation in ComD of S. pneumoniae is also in the DHp domain (85);
and while this residue is conserved in AgrC (T224), the effect of an analogous
mutation in AgrC is not known. Collectively, these results strongly point to the
DHp subdomain as the key to the kinase activation mechanism, yet the question
of how specific ligand binding triggers signal transduction and kinase activation
via the DHp subdomain is open.
The goal of this study was to elucidate the AgrC signal transduction
mechanism and thereby shed light on the mechanism of activation of other
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members of the HPK10 family. Complementary mutants missing either the
phosphorylation site histidine of the DHp subdomain or key catalytic residues in
the CA subdomain exhibited robust activity upon co-expression, revealing that
AgrC activation occurs through dimerization and trans-autophosphorylation.
One possible function of the DHp subdomain constitutive mutations was to
promote

dimerization

as

a

mechanism

for

activation;

however,

co-

immunoprecipitation analysis demonstrated that dimers are pre-formed. In fact,
dimerization appeared to be reduced in at least one of the DHp subdomain
constitutive mutants. By combining the complementary mutants with known
sensor domain mutations that alter ligand specificity (58), heterodimers were
constructed in which signal input is primarily received by only one sensor. Not
only was input from one sensor domain sufficient for activation, but
additionally, either kinase domain was activated irrespective of whether the
functional sensor domain was part of the same protomer molecule. Moreover,
analogous symmetric kinase activation was observed in the absence of ligand in
mutant heterodimers containing one protomer with a DHp subdomain
constitutive mutation. Thus, AgrC activation is inherently symmetric via
bidirectional cross-talk at the dimer interface.
3.2 AgrC is a Pre-formed Dimer that trans-autophosphorylates
The prototypical histidine kinase functions as a dimer and undergoes
trans-autophosphorylation (32, 71). In order to test whether AgrC follows this
paradigm, an intermolecular complementation approach was adopted, similar to
that used to demonstrate functional dimerization and trans-autophosphorylation
for HPKs in E. coli (86-88). The aim was to create and analyze two
complementary mutants, one lacking an appropriate phosphorylation site and
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one with a dysfunctional kinase, neither of which has detectable kinase activity
when expressed alone. When co-expressed, mutant heterodimers would form in
which each protomer would complement the other’s defect only if AgrC
undergoes dimerization and trans-autophosphorylation.
3.2.1 Design, Characterization, and Testing of Complementary AgrC Mutants
Through sequence alignment of the AgrC cytoplasmic domain with that of
other HPKs, conserved residues representing the putative phosphorylation site
(His239) and catalytic motifs were identified (Figure 7). The N-box asparagine
(Asn339) and G-box glycine residues (Gly394 and Gly396) are essential for ATP
binding in other HPKs (89, 90). Accordingly, these residues were mutated in
AgrC-I, and the resulting activities were tested in S. aureus -lactamase reporter
cells (52). As expected, the phosphorylation site mutant H239Q was completely
inactive (Figure 21). Surprisingly, mutation of the N-box (N339D) resulted in
only partially reduced receptor activation unlike the effect of the corresponding
mutation in EnvZ (90). Each individual G-box glycine mutant (G394A and
G396A) exhibited weaker receptor activation than that observed for AgrC-I
N339D, while the double mutant (G394A, G396A) was completely inactive up to
the highest concentration of AIP-I tested (10 μM). Thus, AgrC-IH239Q and AgrCIG394A,

G396A

were selected for subsequent complementation analysis and are

hereafter referred to as AgrC-IHis and AgrC-IKin, respectively, to indicate the
particular defect of each mutant. In order to determine the cellular localization
and expression levels of AgrC-IHis and AgrC-IKin C-terminal GFP-fusions of the
two mutants and WT AgrC-I were constructed. Ligand-dependent kinase
function was preserved in the AgrC-I-GFP fusion protein, as receptor activation
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Figure 21. Probing Conserved Catalytic Motifs in the AgrC HK Domain. lactamase activity of reporter cells expressing the indicated AgrC-I construct
following incubation with or without 10 μM AIP-I, as indicated. Data are
presented as percent maximal activation of WT AgrC-I ± SEM.
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by AIP-I was nearly as effective as that of WT AgrC (Figure 22 and Table 5).
Fluorescence microscopy showed that AgrC-I-GFP localized to the cell
membrane (Figure 23B-D). Images of AgrC-I-GFP expressing cells that produce
AIP allowed direct observation of the autocatalytic induction of agr expression
(30) and showed that AgrC is uniformly localized throughout the cell perimeter
(Figure 23D). Attenuated expression of AgrC-I-GFP in an AIP producing strain
that lacks agrA confirmed that the observed induction of AgrC expression is
dependent on the AgrC-A TCS (Figure 23B). The images of cells expressing
AgrC-I-GFPHis and AgrC-I-GFPKin fusions (Figure 23E, F) resembled those of
uninduced cells (Figure 23B, C) expressing WT AgrC-I-GFP, suggesting that the
phosphorylation site and catalytic domain mutations do not adversely affect
localization.
Previous attempts to characterize several epitope-tagged versions of AgrC
by western blot failed, highlighting the difficulties of working with a polytopic
membrane protein presumed to express at low abundance (55). In this study, a
protocol for preparation of S. aureus membrane fractions was adapted from
MRSA Protocols (91), in which the cells were lysed with osmotic shock following
cell wall removal by treatment with lysostaphin. Four different conditions were
used for resuspension of membrane pellets, and if the samples were boiled prior
to gel loading, no definitive bands appeared for either AgrC-GFP or AgrC-HA
constructs (data not shown). However, when samples were loaded without being
subjected to denaturing conditions, such as boiling, clear bands attributable to
AgrC were detected for all resuspension conditions (Figure 24A). Multiple bands
were detected for AgrC-GFP constructs, including a high molecular weight band
that may represent an AgrC dimer, but none of the bands matched the expected
64


Figure 22. Functional Characterization of AgrC-GFP. -lactamase activities of
reporter cells expressing the indicated AgrC-I construct(s) following incubation
with increasing concentrations of AIP-I. Data are presented as percent maximal
activation of WT AgrC-I ± SEM.

65

"!



 













 

 







 



 



 



 # #



Figure 23. Characterization of AgrC-GFP Constructs by Fluorescence
Microscopy. (A-L) Fluorescence images of AgrC-GFP constructs used in this
study. Scale bars equal 2 μm. (K, L) Images with longer exposure than (A-J) for
an enhanced view of the AgrC truncations, which show lower expression than
the other constructs.
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Figure 24. Characterization of AgrC-GFP Constructs by Western Blot. (A) AntiGFP western blot of membrane fractions from cells expressing WT AgrC-GFP or
AgrC-HA solubilized in RIPA (1.0% NP-40, 0.25% DOC), Triton (1.0%), SDS
(0.1%), or SC (0.1 M sodium carbonate). (B) Anti-GFP western blot of constructs
shown in Figure 23A-H. Sortase is the loading control.

67

Table 5. Activities of AgrC Mutants and Mutant Heterodimers.
AgrC Receptor Variants
WT

His
(H239Q)

Kin
(G394A,
G396A)

AgrC-I
AgrC-I
AgrC-I

AgrC-I
AgrC-I

AgrC-IGFP
AgrC-IGFP
AgrC-IGFP
AgrC-ISensor

AgrC-II

AgrC-IGFP
AgrC-IGFP

AgrC-ISensor

AgrC-ISensor
AgrC-ISensor

AgrC-I
AgrC-ISensor

AgrC-ISensor
AgrC-I

AgrC-II
AgrC-I
AgrC-II

AgrC-II
AgrC-II
AgrC-I

EC50 (nM), (95% CI)

IC50 (nM), (95%
CI)
AIP-III
(+AIP-I)

AIP-I

AIP-II

10, (8.7-13)
–
–
40, (35-45)
16, (14-17)

–
–
–
–
–

nt
n/a
n/a
18, (13-25) *
nt

–

–

n/a

–

–

n/a

36, (31-42)

–

nt

–
–
n/a
–
–
n/a
6100, (4200–
nt
9000)
200, (170-240)
–
140, (88-230) #
310, (260-380)
–
320, (150-650) #
–
2.9, (2.3-3.6)
nt
–
–
n/a
–
–
n/a
21, (18-25)
17, (13-22)
15, 9.8-21) *
17, (16-19)
4.5, (3.6-5.6)
17, (13-22) *

EC50 and IC50 values and 95% confidence intervals are shown for mutants
individually and in combination. – = no activity observed up to the highest AIP
concentration tested (>10 μM). * = 150 nM AIP-I added. # = 1 μM AIP-I added.
n/a = not applicable, the variant is not active. nt = not tested in this study.
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molecular weight of 77 kDa. However, treatment with dilute acid resulted in
appearance of a single band at the appropriate molecular weight (Figure 24B),
suggesting that the acid denatures the protein to some extent without promoting
aggregation. In subsequent experiments, lysis was carried out by incubation of
protoplasts in buffer containing 1.0% nonyl phenoxylpolyethoxylethanol (NP-40)
and 0.25% deoxycholate (DOC), and the resulting total cell lysates were treated
with dilute acid prior to gel loading. Having established conditions for
reproducible western blot analysis of AgrC, the various WT and mutant AgrCGFP constructs were analyzed. Importantly, expression of AgrC-IHis is
comparable to WT AgrC-I, and expression of AgrC-IKin is somewhat reduced but
sufficient for use in the complementation experiment (Figure 24B).
Having established that the individual AgrC-IHis and AgrC-IKin mutants
have no measureable kinase activity and demonstrate adequate expression and
appropriate localization, they were co-expressed by introducing the compatible
plasmids, pEG58 and pEG59, into the reporter strain background (52). In cells coexpressing AgrC-IHis and AgrC-IKin, robust dose-dependent activation by AIP-I
was observed with a slightly increased EC50 value of 40 nM compared to 10 nM
for WT AgrC-I (Figure 25B and Table 5). Similar activation was observed with
the GFP-fused variants (Figure 22). The maximal activity of the mutant
heterodimers was moderately reduced compared to WT AgrC, consistent with
the statistical expectation of the formation of inactive mutant homodimers. In
order to rule out plasmid recombination as a source of active AgrC in this hybrid
strain, plasmid size was confirmed by agarose gel electrophoresis of whole cell
minilysates, and each plasmid was backcrossed to a naïve reporter background
to reconfirm the inactivity of each individual mutant (data not shown).
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Figure 25. Co-expression of AgrC-I Complementary Mutants. (A) Schematic of
a heterodimer formed between AgrC-IHis and AgrC-IKin. (B) Activation curves for
the indicated constructs following treatment with AIP-I. Percent activity is
relative to maximal activation of WT AgrC-I ± SEM. (C) Inhibition of the
complementary pair by AIP-III in the presence of a constant concentration (150
nM) of AIP-I. Percent activity is relative to maximal activation by 150 nM AIP-I ±
SEM.
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To ensure that the complementary mutations do not alter ligand
recognition, the ability of a non-cognate AIP to block AIP-I-induced activation of
the mutant heterodimer was assessed. Treatment of reporter cells co-expressing
both mutants with a fixed concentration of AIP-I and increasing concentrations
of AIP-II or AIP-III resulted in a dose-dependent decrease in activity (Figure 25C
and Table 5). Thus, AgrC-IHis and AgrC-IKin form functional heterodimers that
maintain WT ligand specificity. Collectively, these results demonstrate that
intermolecular complementation occurs between an AgrC-I phosphorylation site
mutant

and

a

catalytic

domain

mutant.

The

possibility

that

AgrC

autophosphorylation may occur in cis was not ruled out, but this study
definitively showed that agr activation can occur via trans-autophosphorylation
of AgrC dimers or higher order oligomers.
3.2.2 AgrC Homodimerizes in the Absence and Presence of AIP
Histidine kinases typically function as dimers (32, 71); however, the
influence of ligands on the oligomeric state has not been investigated for most
HPKs. Two exceptions are VirA of A. tumefaciens (92) and the HPK-associated
aspartate receptor, Tar (93) for which the fundamental dimeric units were shown
to be independent of ligand binding. In order to determine whether AgrC exists
as

a

pre-formed

or

ligand-induced

dimer,

co-immunoprecipitation

of

differentially tagged versions of AgrC in the absence and presence of AIP was
performed. First, cells co-expressing GFP and HA-tagged complementary
mutants, AgrC-I-GFPHis and AgrC-I-HAKin, were analyzed to ensure that
heterodimers formed by AgrC-I-GFP and AgrC-I-HA are functional. This pair
exhibited robust dose-dependent activation by AIP-I, with an EC50 of 31 nM
(Figure

26A).

Next,

immobilized
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GFP

antibodies

were

used

to
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Figure 26. Co-immunoprecipitation of AgrC-I-GFP and AgrC-I-HA. (A)
Activity of reporter cells co-expressing AgrC-I-GFPHis and AgrC-I-HAKin
following treatment with increasing concentrations of AIP-I. Data are presented
as percent maximal activity of this AgrC-I pair ± SEM. (B) Immunoprecipitation
of lysates from cells co-expressing WT AgrC-I-GFP and AgrC-I-HA or AgrCIR238H-GFP and AgrC-IR238H-HA using an -GFP affinity matrix. Asterisk indicates
IgG bands, and bracket indicates AgrC-HA bands. (C) Immunoprecipitation,
including Sortase control, as in (B) except an -HA affinity matrix was used.
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immunoprecipitate AgrC from total lysates of cells co-expressing WT AgrC-I-HA
and

AgrC-I-GFP.

Western

blot

analysis

showed

that

AgrC-HA

is

immunoprecipitated only when AgrC-GFP is present and that AgrC-HA
interacts with AgrC-GFP in the absence and presence of AIP (Figure 26B). Similar
results were obtained when HA antibodies were used to immunoprecipitate the
complex (Figure 26C).
In order to rule out the possibility that these results were due to nonspecific interactions with membrane proteins, the immunoprecipitate elutions
were probed for the presence of Sortase, an unrelated membrane protein
involved in anchoring proteins to the cell wall. While Sortase appeared in the
total lysate inputs, it was not present in the samples eluted from the beads
(Figure 26C). Furthermore, formation of AgrC-GFP/AgrC-HA dimers was not
observed when a mixture of lysates from cells expressing only AgrC-GFP or
AgrC-HA was analyzed by immunoprecipitation (data not shown), indicating
that dimerization occurs only in the cell and not following lysis. These results
confirm the dimeric nature of AgrC and demonstrate that the dimers form
independent of ligand binding.
3.3 The AIP Signal is Transduced Symmetrically within AgrC Dimers
As the complementary mutants allow isolated detection of the activity of
AgrC heterodimers vs. homodimers, they could facilitate activity measurements
of heterodimers containing two different sensor domains. Thus, various aspects
of AgrC signaling were analyzed by combining the complementary mutants with
sensor domain mutants. This experimental system proved to be very powerful
and revealed the surprising result that the AIP signal is propagated both linearly
within one AgrC molecule and laterally across the dimer interface.
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3.3.1 One Intact Sensor Domain is Sufficient for Activation
First, the AIP:AgrC stoichiometry was evaluated by testing whether one
complete sensor domain is sufficient for ligand-induced activity in a heterodimer
containing one truncated sensor domain. N-terminal truncations of both WT
AgrC-I and AgrC- IKin were constructed by deleting progressive segments of the
transmembrane sensor domain. When expressed individually, none of the
resulting homodimers displayed significant activity in response to AIP-I (Figure
27A). However, co-expression of full-length AgrC-IHis with a truncated mutant
lacking most of the sensor domain (AgrC-I1-135, Kin) resulted in significant, dosedependent activity (Figure 27A, B). The maximal activation was significantly
reduced compared to the full-length complementary mutants, which may be due
to poor expression and/or membrane localization of the truncations (Figure 23IL). Nonetheless, one intact sensor domain is sufficient for activation, consistent
with a model of 1:1 AIP:AgrC stoichiometry.
In order to overcome the limitation of poor localization, an analogous
experiment was carried out using a full-length AgrC-I mutant that exhibits
expression and membrane localization similar to WT but greatly reduced
sensitivity to AIP-I (Figure 23G, H and 24B) (58). AgrC-I T104V, S107V, S116I is
approximately 50-fold less sensitive to AIP-I than WT AgrC (58), and for
simplicity, is hereafter referred to as AgrC-ISensor. The phosphorylation site and
catalytic mutations were next introduced into AgrC-ISensor; and accordingly, coexpression of AgrC-ISensor, His and AgrC-ISensor, Kin resulted in very weak activity with
an EC50 value of 6.1 μM (Figure 28C and Table 5). However, when AgrC-IHis was
combined with AgrC-ISensor,

Kin

, activation by AIP-I was restored close to that
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Figure 27. Activities of N-terminally Truncated Variants of AgrC. (A) Activities
of the indicated AgrC-I truncation mutants following treatment with a saturating
concentration (10 mM) of AIP-I. The gray bars represent the activities upon coexpression with full-length AgrC-IHis. (B) Schematic of AgrC-IHis + AgrC-I1-135, Kin
and the activity of that pair following treatment with AIP-I. Individual mutants
and the full-length AgrC-IHis/AgrC-IKin pair are shown for reference. Data are
presented as percent maximal activation of WT AgrC-I ± SEM.
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Figure 28. Analysis of AgrC Mutant Heterodimers Containing Sensor Domains
with Different Ligand Recognition Properties. (A) Schematic of AgrCIHis/AgrC-ISensor, Kin heterodimer with a WT sensor domain linked to a functional
kinase domain. (B) Schematic of AgrC-IKin/AgrC-ISensor, His heterodimer with a WT
sensor domain linked to a dysfunctional kinase domain. (C) Activities of reporter
cells co-expressing the constructs indicated following treatment with AIP-I.
Percent activity is relative to maximal activation of WT AgrC-I ± SEM. (D)
Activities of reporter cells indicated following treatment with increasing
concentrations of AIP-III in the presence of 1 μM AIP-I. Percent activity is relative
to maximal activation of AgrC-IHis/AgrC-IKin by 1 μM AIP-I ± SEM.
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observed for the AgrC-IHis /AgrC-IKin pairing with WT sensor domains (Figure
28A, C and Table 5), consistent with the above observation that only one WT
sensor is required for activation of an AgrC dimer. Additionally, the maximal
activities of heterodimers involving AgrC-ISensor were similar to that observed
with the AgrC-IHis /AgrC-IKin pair, unlike the result with the truncated receptors.
3.3.2 Both AIP-dependent and Constitutive AgrC Signaling is Symmetric
Having established that only one functional sensor domain is required for
activation, the AgrC-ISensor heterodimers were used to test the simple hypothesis
that each receptor protomer transduces the activating signal directly to its own
kinase. In this proposed mechanism of asymmetric activation, only the kinase
domain linked to the functional sensor domain is predicted to be activated. For
example, in the AgrC-IHis/AgrC-ISensor,

Kin

heterodimer, AgrC-IHis contains WT

sensor and kinase domains and phosphorylates AgrC-ISensor, Kin (Figure 28A, C). In
contrast, the reciprocal pair of AgrC-ISensor,

His

and AgrC-IKin is predicted to be

inactive since the functional sensor and kinase domains are located in different
protomers of the dimer and therefore separated (Figure 28B). Surprisingly, AgrCIKin/AgrC-ISensor,

His

exhibited robust dose-dependent activation that was nearly

indistinguishable from that observed for AgrC-IHis/AgrC-ISensor, Kin, as reflected in
the EC50 values of 310 and 200 nM, respectively (Figure 28C and Table 5). The
AIP-I-induced activation of both heterodimeric pairs was inhibited by AIP-III in
a dose-dependent fashion (Figure 28D and Table 5), demonstrating that
antagonism by non-cognate AIPs is maintained and the heterodimers are not
artificially poised for activation. Thus, instead of following the predicted linear
signaling mechanism, AgrC activation appears to be symmetric. Ligand binding
to one functional sensor domain stabilizes or induces conformational changes
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that may be propagated across the dimer interface to activate either kinase
domain. Alternatively, a composite AIP binding pocket formed by both sensor
domains could account for the result, as a 1:2 AIP:AgrC stoichiometry has not
been formally excluded, but this possibility is not supported by the results
obtained with the truncated AgrC variants.
To further test the idea of symmetric signaling by AgrC, heterodimers
were constructed in which the two receptors belong to two of the most divergent
agr specificity groups, I & II. The sensor domains of AgrC-I & II share only 31%
sequence identity, and AIP-I & II are potent cross-group inhibitors (Table 1). The
histidine and CA subdomain mutations were added to AgrC-II, and as with
AgrC-I, the AgrC-IIHis and AgrC-IIKin mutants were completely inactive
individually (Table 5). In this case, the asymmetric, linear model of activation
predicts that only the AIP specific for the sensor domain attached to a functional
kinase would activate an AgrC-I/II heterodimer. For example, only AIP-I would
be expected to activate AgrC-IHis/AgrC-IIKin since only AgrC-I has a functional
kinase (Figure 29A). Conversely, the symmetric model predicts that both AIP-I &
II would activate an AgrC-I/-II heterodimer equally well, regardless of which
protomer harbors the functional kinase domain. In fact, AgrC-IHis/AgrC-IIKin was
activated to approximately the same extent by AIP-I & II, as represented by EC50
values of 21 and 17 nM, respectively (Figure 29C and Table 5). The same result
was obtained upon treatment of the reciprocal AgrC-IKin/AgrC-IIHis heterodimer
with AIP-I or AIP-II (Figure 29B, D and Table 5). Thus, receptors of two
divergent agr groups formed functional heterodimers activated by both cognate
AIPs, lending additional evidence to the conclusion that input from one sensor
domain leads to activation of either kinase domain.
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Figure 29. Analysis of Mutant Heterodimers Containing AgrC Receptors of
   

   

Two Different agr Groups. (A, B) Schematics of AgrC-I/II mutant heterodimers.
(C, D) Activities of the constructs shown above (A, B) treated with AIP-I or AIPII as indicated. (E, F) Activities of (A) and (B) treated with 150 nM AIP-I and
increasing AIP-III. Percent activity is relative to maximal activation of WT AgrC-I
or AgrC-II (C, D) or of AgrC-IHis/AgrC-IKin (E, F) ± SEM.
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To ensure that the ligand recognition by the unnatural AgrC-I/II sensor
domain pairings was not fundamentally changed, inhibition by AIP-III, an
antagonist of both AgrC-I & II, was tested. Indeed, the two complementary
AgrC-I/II mutant heterodimers were potently inhibited by AIP-III (Figure 29E, F
and Table 5).
The model taken from the above results involves propagation of
activating conformational changes across the dimer interface within the
intracellular HK domain, downstream of the ligand-receptor interaction. To test
this model, a recently isolated constitutive DHp subdomain mutant, AgrC-IR238H
(42), was incorporated into complementary mutant heterodimers. R238 is
adjacent to the phosphorylation site histidine (H239) in the predicted
dimerization domain. In the absence of ligand, AgrC-IR238H exhibits full activity,
equivalent to that observed upon treatment of WT AgrC-I with a saturating
concentration of AIP-I (Figure 30C). Like WT AgrC-I, the constitutive mutant
exists as a pre-formed dimer (Figure 26B, C); however, the level of
homodimerization was less than that of the WT receptor, a finding that may be
relevant to the mechanism of the constitutively active receptor.
Provided that AgrC-IR238H assumes the conformational state associated
with normal ligand-dependent receptor activation, the symmetric signaling
mechanism predicts that this conformation can be transduced to a WT AgrC
protomer in a heterodimer configuration, resulting in constitutive transautophosphorylation. To test this prediction, the histidine and G2-box mutations
were introduced to AgrC-IR238H. Individually, the AgrC-IR238H, His and AgrC-IR238H, Kin
mutants were inactive (Figure 30C), confirming that ligand-independent activity
depends on these critical residues. When co-expressed, complementation
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Figure 30.



Ligand-independent Signaling by AgrC Mutant Heterodimers

Containing One Constitutive R238H Mutant. (A) Schematic of AgrC-IR238H,
His

/AgrC-IKin in which the protomer with the constitutive mutation also has a WT

kinase domain. (B) Schematic of AgrC-IHis/AgrC-IR238H, Kin in which the protomer
with the constitutive mutation has a dysfunctional kinase domain. (C) Activities
of reporter cells expressing the indicated AgrC-I constructs following treatment
with or without AIP-I, as indicated. Data are presented as percent maximal
activation of WT AgrC-I ± SEM.
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between the mutants was observed, with constitutive activity reaching a level
similar to that seen with AIP-I-induced activation of the AgrC-IHis/AgrC-IKin
complementary pair (Figure 30C). Next, mutant heterodimers composed of one
constitutive and one non-constitutive receptor were analyzed. The combination
of AgrC-IR238H, His and AgrC-IKin, as illustrated in Figure 30A, resulted in ligandindependent activation at a magnitude nearly as high as that observed with the
homologous AgrC-IR238H,

His

/AgrC-IR238H,

Kin

pairing (Figure 30C). The key

reciprocal combination of AgrC-IHis and AgrC-IR238H, Kin (Figure 30B), in which the
receptor with a functional kinase is missing the constitutive mutation, also
exhibited activity in the absence of AIP-I (Figure 30C), In this case, the
magnitude of activation was about one third of that seen with AgrC-IR238H,
His

/AgrC-IKin, indicating that the symmetry was imperfect. Nonetheless, an

activating conformational change imparted by one point mutation was
transferred between protomers of an AgrC dimer.
3.4 Model of AgrC Signaling
On the basis of these results, a working model of AgrC signal transduction
has been developed in which cognate ligand binding to one or both
transmembrane sensor domains of an AgrC homodimer stabilizes or induces an
active conformational state, in turn stabilizing or inducing a conformational
change in the corresponding cytoplasmic DHp subdomain(s). Intermolecular
interactions across the coiled-coil dimer interface result in functionally parallel
conformational changes in both protomers whether or not they are ligandbound. The concerted adoption of the activated conformational state in both
protomers leads to concurrent phosphorylation of both histidines by the
contralateral kinase subdomains. While the nature of the conformational changes
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responsible for symmetric signaling by AgrC is yet to be determined, they are
likely mediated by coiled-coils in the predicted dimerization (DHp) domain.
There is one published study demonstrating symmetric signaling in an HPK, in
which various chimeras of the aspartate receptor, Tar, and the E. coli osmosensor,
EnvZ, were analyzed (60). The HAMP domain, a small coiled-coil linking the
sensor and HK domains in many HPKs, was determined to be the site of
symmetric signaling within the chimeras, based on the observation that
homologous HAMP domain pairings enabled symmetric signal transduction
through the receptors, whereas heterologous HAMP pairings resulted only in
linear, asymmetric receptor signaling. AgrC and other HPK10 members do not
contain HAMP domains, but their DHp subdomains contain putative coiledcoils. One feasible way a conformational shift could be transmitted between
dimeric receptors is via concerted rotation of the coiled-coils. Structural analysis
of an archaeal HAMP domain by NMR implied that signaling involves a
concerted, gear-like rotational transition between distinct helical packing mode
(61). A rotational activation mechanism has also been suggested for the A.
tumefaciens VirA and yeast Sln1 HPKs, in which the effects of altering the coiledcoil domain helical register were analyzed using N-terminally fused leucinezipper insertions (94, 95).
Stimulus modulation by cross-talk within dimeric receptors may be
adaptive for particular biological functions. Regarding AgrC dimers in
staphylococci, symmetric activation may act as a mechanism for signal
amplification that is important for the physiological process of quorum sensing,
in which a swift, exponential response to a particular concentration of ligand is
desired.
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Chapter 4: Discussion
4.1 Summary and Implications of this Work
In this work, the tools of chemistry and biology were used to extend the
understanding of signal transduction in the agr system of S. aureus. First, a new,
convenient method for the synthesis of AIPs and -thioester peptides was
developed and used to facilitate an analysis of the inhibitory AIP
pharmacophore. While previous AIP structure–activity relationships (SAR) had
revealed that many substantial perturbations do not prevent AgrC inhibition
even though minor changes often result in loss of AgrC activation, the limit of
plasticity of the inhibitory AIP structure was not known. In fact, only two bulky,
hydrophobic amino acids at the C-terminus and an acylated N-terminus must be
present within the thiolactone macrocyclic scaffold to block activation by cognate
AIPs (Figure 20). Second, genetic and biochemical approaches led to the
discovery that AgrC is a pre-formed dimer that transduces activating
conformational change(s) upon AIP binding both linearly within one protomer
and laterally across the dimer interface to the sister protomer, resulting in
symmetric

trans-autophosphorylation.

This

study

was

the

first

direct

investigation of the activation mechanism of AgrC, the S. aureus receptor
histidine kinase of the agr quorum sensing system that controls virulence.
The new synthetic route to AIPs via Fmoc-SPPS described in Section 2.2 is
based on the handle design of Botti et al. (74) but extends this latent thioester
linker concept to any resin type. The thiolactone-containing AIP structure can be
obtained by simply incubating the corresponding protected peptide -oxyester
precursor in aqueous buffer in the presence of a non-nucleophilic reducing agent
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such as TCEP (Figure 12D). Collectively, the data support the cascade-type
mechanism shown, in which the reducing agent first triggers the O-to-S acyl
transfer at the C-terminus, thereby setting up a transthioesterification reaction
between the nascent -thioester and the cysteine sulfhydryl, yielding the
thiolactone with concomitant expulsion of the linker.
In addition to AIP synthesis, the -hydroxy cysteine linker (5) is generally
useful for the preparation of peptide -thioesters for use in native chemical
ligation (76) and expressed protein ligation (96) studies. Most of the AIPs and
AIP derivatives used in this work were synthesized via the -hydroxy cysteine
linker, and in some cases, an automated microwave-assisted peptide synthesizer
was used, highlighting the stability of the linker (Materials and Methods). The
linker was also successfully used in the Fmoc-SPPS synthesis of phosphopeptide
-thioesters for use in protein semisynthesis (Mette Jensen, unpublished).
However, one important limitation is that the stability of the linker is somewhat
sequence dependent. An N-methylated residue (Section 2.3.1) or Gly-Gly
sequence (Kyle Chiang and Maya Bar-Dagan) at the C-terminus of the peptide
prevented attainment of the desired sequences, presumably via diketopiperazine
formation during deprotection of the second amino acid coupled to the resin (80,
81). Nonetheless, this method appears amenable to most peptide sequences and
offers an improved route to Fmoc-based -thioester peptides and AIPs. In
comparison to the method of Botti et al. (74) upon which the linker was based,
this method circumvents the need to repeat the linker installation on every batch
of resin used and avoids the exclusive use of resins that swell in water, which are
difficult to handle and have low loading capacities, resulting in low yields.
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The ability to prepare AIPs via the new Fmoc-SPPS route enabled a
systematic SAR analysis of truncated AIP-II (6), which was previously found to
inhibit S. aureus virulence of all four agr groups (40). The inhibitory activities of
ten trAIP-II analogues were tested against AgrC-II and AgrC-I to evaluate
cognate and non-cognate inhibition, respectively. The rank order of the peptides
according to potency was roughly the same for both receptors, but as potency
decreased, selectivity of the molecules for AgrC-I over AgrC-II increased (Table 4
and Figure 17). Although the main mode of inhibition is still hypothesized to be
competitive antagonism at the orthosteric agonist binding site (41), recent work
demonstrated that some non-cognate AIPs are inverse agonists of some
constitutively active AgrC mutants (42). Of the four S. aureus agr groups, group II
is the most divergent from the others, and inverse agonism was only observed in
AIP–AgrC pairings that included either AIP-II or AgrC-II. Thus, the behavior of
inhibitory AIPs may be more complex than that of neutral antagonists, and the
mode(s) of inhibition may differ depending on the agr groups involved. One or
both of these possibilities may explain why the weakest trAIP-II derivative
antagonists inhibited AgrC-I much more strongly than AgrC-II.
Cross-group antagonism of the agr response by non-cognate AIPs has
been used to attenuate the spread of an infection in an animal model (19). Thus,
understanding the minimal determinants of inhibition by AIP analogues may be
directly applicable to development of an antimicrobial if AgrC proves to be a
viable therapeutic target. The Meth Link analogue (14) of trAIP-II (Figure 15)
encompasses only the elements determined to be required for inhibition in this
study (Figure 20) and may represent a good starting point for further medicinal
chemistry efforts. Although Meth Link is a very poor inhibitor of AgrC-II, it is a
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modest inhibitor of AgrC-I, with an IC50 of approximately 1 μM (Table 4). The
peptidic character of this molecule has already been reduced compared to the
trAIP-II parent peptide via the removal of one amide bond, and its molecular
weight of 504 Da is comparable to small molecule therapeutics. The stability of
the molecule may be significantly improved if a substitute can be found for the
thioester that does not greatly sacrifice inhibitory potency. Notably, such an
analogue could provide important clues to solve the longstanding mystery of the
basis for the importance of the thioester. The results obtained with the Lactam
analogue (15) (Table 4) suggest that an amide is not a good choice. Construction
of a trAIP-II lactone derivative was attempted via a route analogous to that used
to construct full-length AIP-II lactone (19), but the NMR spectra were not
consistent with the expected structure although the product had the expected
mass. The discrepancy was unfortunately not resolved, leaving open the
question of whether an ester is a viable substitution for the thioester in this
context. Nonetheless, the lactone variant may not be worth pursuing considering
that the full-length AIP-II lactone structure differs dramatically from that of
native AIP-II (79), as seen with the lactam derivatives (52, 77, 79). A thioether
linkage, which has been proposed as a stabilizing substitute for the thioester (79),
may be a better option. Another alternative to the thioester may be an Nmethylated amide, as such a substitution in the non-ribosomal peptide
thiocoraline was recently shown to have no effect on the molecule’s antitumor
activity, while the oxyester substitution greatly reduced it (97). Finally, work to
further reduce the peptidic character of the scaffold and explore SAR of the
region lacking important inhibition determinants may prove to increase the
drug-like properties and potencies of these AIP-derived antagonists.
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As noted above, the reasons for the presence of the thioester linkage in
staphylococcal AIPs and the specific requirement of the thiolactone for
significant AgrC activation are unknown. These questions are particularly
intriguing given the fact that thioesters are rarely found in bioactive natural
products. With few known exceptions, such as thiocoraline (98), most thioesters
in biology are used as reactive handles to transfer molecules from one protein to
another protein. Thus, thioester-containing molecules and protein adducts are
typically transient intermediates in biosynthesis or conjugation pathways. In the
cases of at least two thioester-containing natural products, largazole (99) and
lactacystin (100), the parent molecules are inactive and undergo spontaneous or
enzyme-catalyzed modifications to yield active molecules that do not contain
thioesters. Overall, these observations are consistent with the intuitive
hypothesis that thioester linkages are better suited for biological intermediates
than for end products, as thioesters are relatively unstable compared to amides
and esters. In contrast to amides and esters, thioesters lack resonance
stabilization due to the poor overlap between the non-bonding electrons of the
sulfur spd hybrid orbitals and the electrons of the p orbitals of the carbonyl
carbon. Additionally, thiols have lower pKa values then the corresponding
hydroxyls and are therefore better leaving groups.

Given this backdrop of

information, a very appealing hypothesis is that the thiolactone AIPs represent
transient intermediates. Indeed, Lyon et al. proposed that the AIPs may acylate
AgrC (40); however, the results of order-of-addition and wash-out experiments
were not consistent with covalent binding to the receptor (41). As AIPs appear to
be a rare example of bioactive, thioester-containing final products, perhaps the
inherent instability of the thiolactone is advantageous from the perspective of
88

staphylococci in vivo. Spontaneous AIP hydrolysis may contribute to the
temporal control of AIP concentration by preventing excessive accumulation of
AIP at low bacterial population density and/or persistent AgrC activation.
Additionally, RNAIII expression and toxin production decrease in alkaline pH (>
8.0) (101, 102), and AIP hydrolysis may be the mechanism for the observed pH
dependence of agr output.
The role of the AIP thiolactone in AgrC activation in vitro may be related
to structural differences among thioesters, esters, and amides that are subtler
than the pronounced differences in stability. The resonance stabilization of
amides and esters imparts rigidity, whereas thioesters are more flexible. The
differences in NMR chemical shifts observed among AIP-II lactam and AIP-II
lactone derivatives and native AIP-II suggest that the rigid amide and ester
substitutions may change the overall structure of the AIP macrocycle such that it
can no longer activate AgrC (52, 77, 79). If so, a thioether linkage may be the ideal
thioester substitute to test this possibility and to improve the therapeutic
potential of AIP antagonists by imparting stability without sacrificing flexibility.
The mechanistic analysis of AgrC in Chapter 3 yielded the first definitive
insights into the activation mechanism of a polytopic, peptide-sensing receptor
histidine kinase. Intermolecular complementation of histidine phosphorylation
site and kinase domain mutants and co-immunoprecipitation of differentially
tagged AgrC variants demonstrated that AgrC is a pre-formed dimer that
undergoes trans-autophosphorylation. The mechanistic link between AIP
binding to an AgrC dimer and the consequential signal transduction to the
kinase

domains

was

investigated

by

further

elaborating

the

robust

complementation scheme. Several sensor domain variants were combined with
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the complementary mutants to construct AgrC heterodimers in which signaling
by individual protomers could be tracked. The observation of ligand-induced
activation by a pairing between a truncated receptor and an intact one suggested
that one AIP binding event per dimer is sufficient for activation and that the
AIP:AgrC stoichiometry is 1:1. Activation in this configuration was rather weak,
possibly due to poor expression and incomplete membrane localization of the
truncated mutant. To circumvent these limitations, full-length AgrC-ISensor
mutants were used in which only three sensor domain residues are changed,
resulting in a 50-fold reduction in the response to AIP-I (58). Accordingly,
activation levels of pairings between one AgrC-ISensor mutant and one WT sensor
domain were restored to the magnitude observed with the initial complementary
heterodimers containing two WT sensor domains. Remarkably, receptor
activation was unaffected by whether or not the sensor domain directly linked to
the functional kinase was mutated. Thus, a signal received by one sensor led to
activation of either kinase domain, indicating that the mechanism of signal
transduction is symmetric within AgrC dimers. Further support for this concept
was provided by constructing heterodimers of receptors belonging to the two
most divergent agr specificity groups, I & II. Although AIP-I is an antagonist of
AgrC-II and vice versa, both AIP-I & II activated mutant AgrC-I/II heterodimers
equally well. Finally, using a constitutive mutant with a single amino acid
change in the DHp domain, activation of a non-constitutive receptor in the
heterodimeric

configuration

was

observed,

demonstrating

that

independent activity is also symmetrically transduced within a dimer.
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ligand-

One key to these results was the ability to directly detect AgrC expression
and localization, which had previously been elusive (55). A few important
technical considerations enabled the use of fluorescence microscopy and western
blot of epitope-tagged variants of AgrC to characterize the mutants used in the
study and analysis of AgrC dimers by co-immunoprecipitation. Despite the
hypothesis that low abundance of AgrC prevented its visualization (55), past
difficulties in detecting AgrC by western blot are most likely attributable to
incompatibility of standard denaturation procedures with AgrC, a polytopic
membrane protein. Boiling samples prior to gel loading reproducibly resulted in
a lack of bands in the western blot, possibly due to aggregation of AgrC (data not
shown). Similarly, certain lysis procedures could result in a failure to recover an
adequate amount of AgrC for detection. In this study, osmotic shock and
detergents were both successfully used to lyse S. aureus cells and subsequently
detect AgrC in samples that were either treated with dilute acid or that did not
undergo any denaturation step at all (Materials and Methods). There are
innumerable potential applications for techniques that enable monitoring of
AgrC protein levels and localization, and these new tools are expected to greatly
aid in future investigations of AgrC (see Section 4.2).
The efficacy and potency of AIP-I toward the initial AgrC-IHis/AgrC-IKin
complementary pair was moderately reduced compared to WT AgrC (Figure 25
and Table 5). The drop in efficacy is consistent with the possibility of a statistical
mixture of dimers that includes inactive mutant homodimers and the loss of one
out of two potential phosphorylation sites per heterodimer. The explanation for
the modest change in potency indicated by the change in EC50 from 10 to 40 nM
is less readily apparent. The EC50 values depend on three unknown quantities, as
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described in the following equation from Black and Leff’s operational model of
agonism (103):
EC50 = KA/(1 + ([RT]/KE)).
KA is the agonist (AIP) affinity for the receptor (AgrC), [RT] is the total receptor
concentration, and KE is the concentration of agonist-bound receptor that elicits a
half-maximal response. This equation is used for standard sigmoidal curves with
Hill Slopes equal to one, as is the case for the AgrC reporter assay results.
Presumably, the KA of AIP-I for WT AgrC is the same as that for the
complementary AgrC mutants, as the sensor domains are identical in WT AgrC,
AgrCHis, and AgrCKin. According to the analysis of AgrC expression levels by
fluorescence microscopy and western blot (Figures 23 and 24), there is little to no
difference in expression between WT AgrC and the complementary mutants,
suggesting that [RT] also remains relatively constant in these experiments.
However, the total concentration of agonist-bound AgrC that elicits a halfmaximal response, KE, is predicted to increase due to AIP-I binding to the
inactive mutant homodimers and the availability of only one out of two
phosphorylation sites per active heterodimer. The KE would change further if the
complementary mutations alter events downstream of AgrC activation, such as a
change in the affinity between AgrC and AgrA. Thus, both the observed decrease
in efficacy and increase in EC50 are most likely due to an increase in KE caused by
formation of inactive AgrC homodimers and the loss of one phosphorylation site
per active mutant heterodimer.
In the mutant heterodimers formed by AgrC-I & II, the maximal activation
levels were further decreased, reaching maximum levels of approximately 4060% of that observed for AgrC-IHis/AgrC-IKin (Figure 29C, D). This result could
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reflect a decreased propensity for the divergent receptors to form dimers,
especially if the sensor domains interact at the dimer interface. Coimmunoprecipitation analysis of complementary AgrC-I/II mutant heterodimers
could be used to test this possibility. The differential effects of the ligand on each
protomer could also result in submaximal signaling by the receptor complex. For
example, if AIP-I, an inverse agonist of a constitutive AgrC-II mutant (42),
stabilizes or induces an inactive state of AgrC-II, this effect could interfere with
an activating conformational change transduced by AgrC-I. Nonetheless, the
agonist-induced activation outweighs any interfering effects as evidenced by the
robust activation of AgrC-I/II mutant heterodimers by AIP-I and AIP-II.
Inhibition tests of the heterodimers using AIP-III confirmed that the
artificial pairings maintained native ligand recognition. However, there was an
unexpected subtlety to some of the dose-response curves in which AIP-III
appeared to act as a partial agonist at low concentrations. For example,
concentrations of AIP-III between 0.5 and 50 nM increased activation of AgrCIHis/AgrC-IIKin by AIP-II (Figure 31A) but not by AIP-I (Figure 31B). To a lesser
extent, the same effect was observed for AIP-III inhibition of AgrC-IKin/AgrCISensor, His (Figure 31C). In both cases, AIP-III slightly increased activation at low
concentrations only when the mutated kinase was linked to the sensor domain
that could perceive the AIP agonist, although AgrC-IIHis/AgrC-IKin did not follow
this trend when AIP-I was used as the agonist (Figure 31B). The biphasic doseresponse curves may be indicative of an allosteric binding site for AIP-III that
remained undetected until now since this effect is only observed when the linear
pathway for receptor signaling is blocked. An analogous effect called functional
selectivity, in which the same ligand acts as a partial agonist or antagonist of the
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Figure 31. Inhibition of AgrC Mutant Heterodimers by AIP-III. (A, B) AIP-III
inhibition of AgrC-I-II heterodimers activated with AIP-II (A) or AIP-I (B). (C)
Inhibition of AgrC-ISensor heterodimers activated by AIP-I as in Figure 28D. Error
bars represent SEM.
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same receptor depending on the context, is attributed to allosteric binding sites in
G-protein coupled receptors (GPCRs) (104). Moreover, in some cases, particular
effects of the allosteric agonists are only observed in the presence of an
orthosteric agonist (104, 105). Alternatively, the apparent partial agonism of AIPIII could be an artifact of the heterodimeric pairings. The development of a direct
AgrC binding assay would be an invaluable tool to test for allostery and to better
understand the mechanisms of inhibition and inverse agonism.
The ligand-independent activation level of the heterodimer in which the
receptor with the R238H mutation had a mutated kinase domain (Figure 30B)
was approximately one third that of the heterodimer in which the receptor with
the R238H mutation had a WT kinase domain and mutated phosphorylation site
(Figure 30A). This imperfect symmetry of signaling by the AgrC R238H mutant
may be a clue to the mechanism of this mutant’s constitutive activity. Since the
AgrC activity was weaker when the R238H mutation was directly adjacent to the
H239 phosphorylation site of the same protomer, the constitutive effect of the
R238H mutation is neither to recruit the kinase domain to the H239
phosphorylation site nor to cause a conformational change that exposes the
adjacent H239 for phosphorylation. Instead, the R238H mutation appears to
confer constitutive activity mainly via a direct, cis effect on the C-terminal kinase
domain of its own protomer and secondarily via an indirect, trans effect on the
kinase domain of the sister protomer mediated by intermolecular interactions
between the two coiled-coils. A second, less favorable possibility is that the
R238H mutation mainly promotes an activating conformational change in the
sister protomer, which is indirectly transduced to its own coiled-coil and kinase
domain via intermolecular interactions at the dimer interface. Although the
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former is simpler and ostensibly more likely than the latter, both hypothetical
mechanisms could contribute to the low ligand-independent activity observed
when the receptor harboring the constitutive mutant lacks a functional kinase
domain.
Based on all of the results presented in Chapter 3, the working model of
AgrC signaling is that AIP binding to a pre-formed dimer triggers symmetric
conformational changes in both protomers directly and/or by intermolecular
interactions at the dimer interface (Figure 32). Thus, whether one or both
protomer(s) is ligand-bound, they are both activated, resulting in transautophosphorylation by both kinase domains. This activation mechanism is
predicted to be mediated by the putative coiled-coil in the DHp subdomain, the
probable site of dimerization. Most of the point mutations within the cytoplasmic
HK domains of AgrC and other HPK10 receptors found to confer constitutive
activity were localized at or very near the putative coiled-coils of the receptors
(42, 84, 85). Together, these results suggest that symmetric signaling via
concerted conformational changes at the coiled-coil dimer interface may be a
general mechanism of activation by quorum sensing HPK10 receptors. Beyond the
HPK10 family, evidence for symmetric signaling via the coiled-coil HAMP linkers
of distantly related HPKs was obtained using chimeric mutants of aspartate
receptor, Tar, and the osmosensor, EnvZ (60). However, in the case of HPKs such
as EnvZ, which sense a general property of the extracellular environment as
opposed to discrete chemical ligands, the role of symmetric signaling would
necessarily be something other than activating an unliganded sister protomer
within a dimer. Perhaps, symmetric signaling could serve to reinforce activating
conformational changes and stabilize the activated state. Further study will be
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Figure 32. Model of AgrC Signal Transduction. Upon binding of one AIP
molecule to an AgrC dimer, a conformational change (orange arrow) is
transferred both linearly, to the kinase domain of the liganded protomer, and
laterally, across the dimer interface (top). As a result, both kinase domains are
activated and trans-autophosphorylate. Additionally, a second AIP binding event
may occur (bottom), reinforcing the conformational changes in both protomers
and thereby further stabilizing the active state.
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required to probe the extent to which symmetric signaling is a general
mechanism of HPK activation.
In the eukaryotic GPCRs, another class of polytopic receptors in which
dimerization is important (106), conformational changes transduced across the
dimer interface have been recently observed. In analyses of purified leukotriene
B4

GPCR

dimers

labeled

with

spectroscopic

probes,

intermolecular

conformational changes were shown to be transmitted between a ligand-bound
protomer and an unbound one (107). However, these conformational changes
were asymmetric (107) and not sufficient to activate the G-protein associated
with the unliganded protomer (108). In another study, FRET experiments used to
track specific ligand-induced conformational changes within μ-opioid and 2Aadrenergic receptor heterodimers revealed that interprotomer cross-talk resulted
in inhibition of G-protein activation (109). Finally, co-expression of two inactive
somastatin-5 (SSTR5) receptor mutants, one that hampered ligand binding and
one that disabled signaling, restored activity (110), indicative of symmetric
signaling analogous to that observed by AgrC.
The various concerted conformational changes observed in different
GPCRs and AgrC may be indicative of an adaptive value of fine-tuned, concerted
conformational changes within dimeric receptors for particular biological
functions. The ability to modulate stimuli by this type of mechanism may be a
major reason why some receptors dimerize or oligomerize instead of simply
functioning as monomers. In bacteria, amplification of the autoinducing signal
by this mechanism may be particularly beneficial for cell density-dependent
processes regulated by quorum sensing receptors, such as virulence, competence,
and bacteriocin production (31).
98

4.2 Future Directions
4.2.1 AIP–AgrC Cross-linking
Previous investigations of the AIP binding determinants within the AgrC
sensor domain relied on powerful and readily available genetic methods: sitedirected mutagenesis (58, 62); construction of chimeric receptors between
different agr groups (55); and error-prone PCR followed by activity
screening (42). Individual residues responsible for inhibition of AgrC-I (42) and
group-specific interactions of agr groups I & IV (58, 62) were identified, as well as
a putative hydrophobic pocket essential for AIP binding (55) (see Section 1.2.3).
In order to build on these findings, work is underway to precisely locate the AIP
binding site(s) via covalent AIP–AgrC cross-linking. To this end, AIP-I & II
derivatives containing photo-activatable cross-linkers at the N-terminus or in
place of a natural amino acid were designed and constructed (Figure 33). First,
benzophenone was chosen as the cross-linking moiety, and the amino acid pbenzoylphenylalanine (Bpa) was added to AIP-II. Two opposing considerations
guided the placement of Bpa within the AIP-II amino acid sequence. Installment
of the cross-linker in place of or adjacent to residues known to be critical for
AgrC activation may maximize the probability that it will contact the receptor
and form a productive cross-link at the binding site. However, this benefit is lost
if the cross-linker reduces the AIP affinity for the receptor, suggesting that the
cross-linker should be positioned away from critical activation determinants.
Thus, Bpa was installed at various positions in the AIP-II sequence, namely Ala4,
Ser6, Ser7, and the N-terminus. Although Phe9 is both a key residue for
activation and the amino acid that most closely resembles Bpa, AIP-II F9Bpa was
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Figure 33. Structures of AIP Derivatives Containing Cross-linkers.
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not made since a similarly bulky naphthylalanine substitution at that position
rendered the peptide inactive (55). A biotin handle was added to the N-terminus
of each peptide for detection, and control peptides lacking the biotin
modification were also prepared to assess its effect on activity. The linear
versions of the cross-linker AIP-II analogues were obtained, but the cyclization
reactions of AIP-II Ala4Bpa, Ser6Bpa, and Ser7Bpa were low yielding, likely due
to interference by the bulky benzophenone side chain (data not shown). Only
AIP-II with Bpa coupled to the N-terminus (AIP-II-Bpa-Biotin (17), Figure 33)
was successfully cyclized and subsequently tested for its ability to activate AgrCII. Although the control peptide AIP-II-Bpa (18) exhibited moderate activation of
AgrC-II as compared to that of AIP-II, AIP-II-Bpa-Biotin (17) was completely
inactive (Table 6) and therefore could not be used in cross-linking experiments.
Subsequent AIP cross-linkers were designed using a photo-reactive
analogue of methionine, photo-Met (pMet) (111). The photo-reactive moiety is a
diazirine that replaces the thioether sulfur of methionine (Figure 33) and
decomposes to a carbene upon irradiation with 330–370 nm light. pMet is
sterically similar to methionine; thus, replacement of methionine by pMet in an
AIP was anticipated to be a minor perturbation that would not impede AIP
cyclization and permit genuine interactions with AgrC. In AIP-I, methionine is
the C-terminal amino acid, one of the two hydrophobic residues hypothesized to
interact with a hydrophobic pocket in the receptor (55). Thus, AIP-I M8pMet was
constructed with and without biotin (19, 20) and tested for activity against AgrCI (Figure 33 and Table 6). Unlike Bpa, pMet was not commercially available, and
Fmoc-pMet was synthesized by Frej Tulin and Matthew Pratt of the Muir Lab
(112). Cyclization reactions of AIP-I M8pMet and AIP-I M8pMet-Biotin
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Table 6. Activities of AIP Derivatives Containing Cross-linkers
AIP Derivative

AgrC Activation EC50 (nM), (95% CI)

AIP-II
AIP-II-Bpa-Biotin (17)
AIP-II Bpa (18)
AIP-I
AIP-I M8pMet-Biotin (19)
AIP-I M8pMet (20)

12, (4.9-27)
–
59, (23-150)
15, (13-18)
144, (37-565)
2.5, (1.4-4.3)

– = no activity up to the highest concentration of AIP tested, >10 μM.
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proceeded without difficulty, and the substitution of pMet for methionine
actually improved potency against AgrC-I (Table 6). The additional biotin handle
caused a reduction in activity, but with an EC50 value of 140 nM, AIP-I M8pMetBiotin (19) was determined to be suitable for further use in cross-linking studies.
Work is currently underway to cross-link 19 to AgrC-I.
Methionines are only present in AIP-I & IV (Figure 3), but cross-linkers
that resemble other natural amino acids are also available. For example, photoleucine

and

photo-isoleucine,

two

additional

diazirine

containing

analogues (111), could be used in place of leucine in AIP-II & III and isoleucine in
AIP-I, III, & IV; and azido and nitro-phenylalanine analogues (113) could be used
in place of phenylalanine or tyrosine in all four AIPs. Use of these additional
cross-linking AIP analogues, in which positions of the cross-linking amino acids
are varied, may facilitate more complete mapping of the AIP binding site(s) on
AgrC as well as enable comparison of cognate and non-cognate binding sites in
the four S. aureus AgrC receptors.
4.2.2 Inhibition of AgrB (This work was performed in collaboration with
Matthew Pratt.)
In addition to inhibition of cognate AIP–AgrC interactions, another
possible mode of agr interference is targeting of AgrB processing of its
propeptide substrate. Based on evidence that AgrB is a cysteine protease (43), the
enzyme may be inhibited by epoxysuccinyl derivatives known to target this class
of enzymes (114). A bona fide AgrB inhibitor of this type would provide strong
support for the proposal that AgrB is in fact a cysteine protease, and perhaps the
identity of the catalytic cysteine could be confirmed (43). Furthermore, AgrB is a
potential therapeutic target, perhaps more promising than AgrC since prevention
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of AIP biosynthesis may be a more effective way to block agr activation than
administering competitive AgrC antagonists. Thus, an epoxysuccinyl peptide
(26) designed to inhibit AgrB was constructed (Figure 34).
Like many other cysteine protease inhibitors (114), the AgrB inhibitor
design was based on the natural product E-64 (Figure 34), the first reported
epoxysuccinyl peptide cysteine protease inhibitor (115). In order to be recognized
by AgrB, the conserved Asp-Glu dipeptide at the P1’ and P2’ positions (Figure 4)
was incorporated in the molecule, and the electrophilic epoxysuccinyl moiety
was appended at the P1 position (Figure 34). The carboxylic acid functionalities
were protected as esters to promote passage across the cell membrane where
they would presumably be removed by non-specific esterases. In order to
synthesize desired product 26, each N-Boc-protected amino acid was activated as
a pentafluorophenyl ester (21 and 22). An azide handle was appended to the
resulting glutamate (22) by acylation with N,3-dibromopropan-1-ammonium
(23), followed by displacement of the bromide with sodium azide to form
intermediate 24. Following deprotection of the glutamate Boc group with TFA,
the aspartate ester (22) and glutamate 24 were coupled to form dipeptide 25.
Finally, the epoxysuccinyl pentafluorophenyl ester, which was synthesized by
Matt Pratt, was coupled to the dipeptide to form the final product (26).
AgrB inhibition by epoxysuccinyl peptide 26 was assessed by testing its
ability to block AIP biosynthesis. S. aureus cultures of agr group I strains were
grown in the presence of various concentrations of 26, and the supernatants were
collected and added to -lactamase reporter cells. Unfortunately, the addition of
the peptide inhibitor had no effect on the supernatants’ ability to activate AgrC
(data not shown), indicating that it did not block AIP biosynthesis and secretion
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Figure 34. Synthesis of Cysteine Protease Inhibitor Designed for AgrB. The
natural product E-64, the first reported epoxysuccinyl peptide cysteine protease
inhibitor is shown.
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into the medium. In order to rule out the possibility that AIP production occurs
before the peptide passes through the membrane, is deprotected by esterases,
and reacts with AgrB, the experiment was repeated with cells that received two
treatments of peptide 26. After the first treatment, the supernatants were
removed, and the cells were re-suspended in medium containing the inhibitor a
second time. However, the same result was obtained. In future efforts, direct
labeling of an epitope-tagged version of AgrB in cells or in vitro could be probed
by western blot with an azide-reactive detection agent such as phosphine-biotin.
The most definitive experiment would be to purify AgrB and add the inhibitor
without the ester protecting groups in vitro. Alternatively, if AgrB purification
proved prohibitive, labeling of AgrB could be attempted in S. aureus lysates.
4.2.3 Quantitative AIP–AgrC Binding Assay
While the agr -lactamase reporter assay (52) has been an incredibly
powerful and useful tool in the study of agr, it has limitations nonetheless.
Specifically, direct investigation of the receptor–ligand interactions are not
possible since the output is a transcriptional read-out downstream of AgrC
activation. The development of a direct AIP–AgrC binding assay would
immediately help resolve several outstanding questions in the field. First, the
binding constants of cognate and non-cognate AIPs could be determined with
WT and mutant variants of AgrC missing important determinants for groupspecific activation (58, 62). Accordingly, any cooperative effects exerted upon
AIP binding to AgrC dimers may be delineated. A direct binding assay would
also facilitate definitive determination of the mode(s) of inhibition by noncognate AIPs (competitive, non-competitive, or uncompetitive) using classical
techniques. Finally, the ability to detect AIP–AgrC cross-links (Section 4.2.1) may
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be a useful tool to ensure that AgrC is properly folded following isolation for a
binding assay; and conversely, a binding assay system could be a useful tool to
increase the yield of AIP–AgrC cross-linking. These advances would be a
tremendous complement to previous investigations and significantly increase
understanding of the agr system.
Thus far, a major obstacle to developing a direct AIP–AgrC binding assay
has been the isolation of AgrC. Attempts in the lab to over-express and purify
AgrC from E. coli have been unsuccessful. However, AgrC dimers were
successfully

isolated

by

co-immunoprecipitation

(Section

3.2.2).

These

experimental conditions, in which AgrC intermolecular interactions are
maintained, are a key step toward the development of conditions to isolate AgrC
for a binding assay. Future efforts are aimed at inducing expression of AgrC in
S. aureus and incorporating the receptor into nanoscale apolipoprotein bound
bilayer (NABB) particles, as done previously with GPCRs (116, 117).
4.2.4 AgrC Structure and Further Mechanistic Insights
Although AgrC was shown to be activated via symmetric signaling (see
Section 3.3), the structural consequences accompanying this mechanism remain
unknown. Thus, the successful application of NMR or crystallographic methods
to determine the structure of AgrC in different activation states would be
extremely informative. As AgrC is a polytopic membrane protein, determination
of the structure of the full-length protein is expected to be very challenging. Even
elucidation of the entire cytoplasmic HK domain structure could be equally
difficult, as the first complete HK domain crystal structure of a sensor histidine
kinase was only recently determined (118). Nonetheless, a structure of only one
subdomain may provide great insight into remaining mechanistic questions
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regarding AgrC. For example, dimerization plays a key role in the function of
AgrC (see Section 3.2), and a crystal structure of the putative coiled-coil
dimerization (DHp) subdomain could reveal the location and intermolecular
contacts of the dimerization interface. Computational programs that predict the
presence of coiled-coils in proteins are available (119) and could be used to
design constructs for crystallization. In addition to the WT DHp subdomain,
structural studies of a construct containing the R238H constitutive mutant may
provide insight into the mechanism of ligand-independent activity and reduced
propensity for homodimerization (Figure 26) imparted by the mutation.
As proposed above, symmetric signaling by AgrC may be important for
efficient kinase activation at the appropriate AIP concentration. This possibility
could be tested by comparing WT AgrC activity in the -lactamase reporter assay
with that of an AgrC mutant that can undergo only asymmetric signaling. In this
way, the effect of symmetric signaling on activation efficacy and EC50 may be
determined. The biggest challenge in this experiment would be to find an AgrC
mutant containing change(s) in the coiled-coil sequence that disrupt
intermolecular

interactions

required

for

symmetric

signaling

but

not

dimerization or asymmetric signaling. One good starting point for finding such
mutants would be an AgrC coiled-coil structure, if available. Alternatively, the
library of AgrC-I mutants already generated via error-prone PCR by Geisinger et
al. (42) could be used. In this experiment, AgrC mutants that signal
asymmetrically would be isolated by a process of elimination. First, the mutants
would be screened for activity in the presence of AIP-I, and any mutants
previously identified as constitutively active (42) would be eliminated. Next,
variants that signal symmetrically would be eliminated by testing for
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complementation between the remaining AgrC-I mutants and AgrC-IIKin in the lactamase reporter assay. Those that can signal symmetrically would be activated
by AIP-II and eliminated, while AgrC-I mutants that can signal only
asymmetrically would not form functional heterodimers with AgrC-IIKin and fail
to be activated by AIP-II. In the final elimination step, co-immunoprecipitation
analysis would be performed to remove mutants that are not pre-formed dimers.
Notably, the discovery of any mutants that fail to exhibit dimerization would not
be useful in this experiment, but they would be extremely interesting for further
study, as they may undergo cis-autophosphorylation. Finally, the contribution of
symmetric signaling to overall AgrC activity may be determined by comparing
the AIP-I-induced activities of the selected mutants to that of WT AgrC. One
caveat to this experiment is that symmetric signaling may contribute only to the
kinetics of activation, and this effect would not be observed in the reporter assay.
Thus, the potential result of no change between the activities of WT AgrC and
asymmetric signaling mutants would be uninterpretable. Secondly, the
asymmetric signaling mutants may alter signaling in unpredictable ways
independent of blockage of symmetric signaling. In this case, the activities of
different asymmetric signaling mutants would vary and prevent determination
of the specific contribution of symmetric signaling to AgrC activity. Nonetheless,
such an outcome may lead to new insights into the AgrC signaling mechanism.
A second hypothesis generated from the results described in Chapter 3 is
that symmetric signaling may be a general phenomenon among quorum sensing
receptors, especially those of the HPK10 family of AgrC. In order to test this
possibility, the predicte coiled-coil region of AgrC could be replaced with that of
other HPK10 family members in the context of the complementary mutant
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schemes and tested for symmetric signaling as described in Chapter 3.
Furthermore, mixed combinations could be used to determine whether a
heterodimer containing two different coiled-coils still signals symmetrically.
A major outstanding question regarding the mechanism of AgrC
activation is whether, in the ground state, the phosphorylation site histidine is
occluded from the catalytic (CA) kinase domain or the CA domain is held an
inactive conformation, apart from the phosphorylation site. In other words, does
AIP binding trigger solvent exposure of the phosphorylation site histidine or
release of the CA domain, or both? One experiment that may delineate between
these possibilities is co-expression of a construct containing the sensor and DHp
domains with a construct containing the CA subdomain in trans in the lactamase reporter assay (Figure 35). If, in WT AgrC, the phosphorylation site
histidine is occluded from the kinase prior to ligand binding, activation would
only occur upon addition of AIP. Alternatively, if the kinase is held in an inactive
conformation or apart from the phosphorylation site prior to activation, coexpression of the constructs would be predicted to result in constitutive activity.
In a similar experiment involving EnvZ of E. coli, kinase activity was successfully
reconstituted via trans expression of the DHp and CA subdomains (120),
although the sensor domain was absent. A critical assumption in this experiment
is that native conformational changes triggered by AIP binding will be
transduced from the sensor domain to the DHp subdomain regardless of
whether a CA subdomain is present in cis or trans. Nonetheless, if this
assumption is incorrect, the outcome would likely be lack of activity, and an
alternative approach could be to co-express the full-length AgrC-IKin mutant and
the WT CA subdomain.
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Figure 35. Experimental Scheme for trans Expression of AgrC Domains. (A)
Two possible mechanisms of AgrC activation. Either the CA subdomains are
held away from the target phosphorylation sites or the phosphorylation site
histidines are occluded from CA subdomains. Upon addition of AIP, the restraint
is removed. (B) If AgrC is split between the DHp and CA subdomains and
expressed in trans, activity is predicted to be constitutive or ligand-dependent,
based on the two hypothetical mechanisms.
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4.2.5 The in vivo Role of agr in Virulence
The role of agr activation and cross-group interference in establishment
and maintenance of S. aureus infection is a critical, unresolved problem in the
field (121). Certain diseases such as toxic shock syndrome are correlated with a
certain agr group (122), while others such as cystic fibrosis are associated with all
four agr groups (123), and indeed some patients are colonized with two or three
different groups. There are also varying results regarding the influence of agr
group identity on host colonization. In one study of patients infected with
S. aureus, a significant number of individuals were colonized with multiple agr
groups (124). In contrast, a separate analysis of the nasal flora of healthy
volunteers yielded no incidences of multiple agr group colonization of S. aureus,
although many participants harbored multiple agr groups of S. epidermidis (125).
Since cross-group interference has no direct effect on growth, it is unlikely to
impact commensal colonization. Instead, certain agr groups may have a survival
advantage in certain niches. In an insect model of virulence, a correlation was
found between relative fitness and specific agr groups by monitoring their
population densities before and after infection within a mixed culture (126).
Thus, there is a plausible role for interference in infection, but it is also
conceivable that certain agr groups have an enhanced ability to carry out a
particular disease process unrelated to cross-group inhibition.
The temporal regulation of agr in vivo has been examined by Wright et
al. (127) who used an agr P3::lux reporter system to monitor agr activation in real
time in a mouse abscess model of S. aureus infection. As expected, agr was
activated a few hours after injection of the bacteria, and this initial burst of
activity lasted only a few hours. Remarkably, a second burst of agr activity was
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observed approximately 72 hours after the initial infection. This behavior does
not represent a temporary diminishment of the bacterial population based on
consistent cell density; although it may be indicative of low metabolic activity or
phagocytosis by neutrophils. Co-injection of a non-cognate AIP with the bacteria
led to a reduction in agr activation at the early time points and, importantly, no
abscess formed over five days. Interestingly, the second burst of agr activity did
not occur in this case, suggesting that the initial burst of agr activity is required
for the resurgence. This result was especially surprising considering that the AIP
half-life is a few hours in serum (127). Analogous experiments in which mice
were injected with agr- strains confirmed that agr activation is required to
establish an infection in this experimental model.
Despite considerable evidence that virulence of S. aureus strains lacking a
functional agr locus is attenuated and are not competent to establish infection
(18-21, 127), many drug-resistant strains and clinical isolates are paradoxically
missing a functional agr locus (16, 128-130). At least some of these dysfunctional
agr mutations arise following the initial establishment of infection (131), and
mixed populations of agr+ and agr- strains have been isolated from the same
individual (131, 132), raising the possibility that agr activation by part but not all
of the bacterial population is required for infection. Perhaps a subsequent loss of
agr function confers an advantage for long-term survival in the host due to the
metabolic demand of agr activation. In any case, the fundamental question of
whether S. aureus can cause an infection without agr activation has yet to be
definitively answered. Thus, the viability of agr as a prophylactic or therapeutic
target is promising but unknown pending future work in this area.
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4.3 Conclusion
The work presented here elucidated several mechanistic features of the agr
system and produced methods expected to aid greatly in future studies. The
identification of the minimal determinants for AIP inhibition of AgrC lays a
foundation for future medicinal chemistry efforts to increase the physiological
stability and efficacy of potential AIP-based therapeutics. The finding that AgrC
activation occurs via symmetric signaling by pre-formed dimers represents a
significant advance in the mechanistic understanding of AgrC, and the
development of fluorescence imaging and western blot analysis of AgrC
provides the long awaited ability to monitor receptor expression. Intriguing
future directions for investigation of agr include analysis of AIP–AgrC
interactions by cross-linking and direct binding assays, elucidation of the
structural basis for AgrC symmetric signaling, and clarification of the
significance of agr in infection.
Whether or not agr proves to be therapeutically relevant, a deeper
understanding of the mechanisms that contribute to virulence will increase
knowledge of S. aureus infections and provide the foundation for new discoveries
and eventual advances in treatment. The insights described in this work will
hopefully be applicable to other quorum sensing receptors and serve to build
connections between the molecular mechanisms of AgrC activation and
inhibition and S. aureus virulence in vivo.
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Chapter 5: Materials and Methods
Materials. Amino acids, HBTU, HATU, PyBop, and Rink and MBHA resins were
purchased from Novabiochem (San Diego, CA) with the exceptions of Boc-Nmethylphenylalanine (Fluka, Buchs, Switzerland) and Fmoc-DAPA(Boc)-OH
(Neosystem Laboratoire, Strasbourg, France). All solvents were obtained from
Fisher (Pittsburgh, PA), and trifluoroacetic acid was obtained from Halocarbon
(River Edge, NJ). All other chemical reagents, including DNase and poly-lysine
solution, were purchased from Sigma Aldrich (Milwaukee, WI). Oligonucleotide
primers were synthesized by Integrated DNA Technologies (Coralville, Iowa).
QuikChange

kits

for

site-directed

mutagenesis

were

obtained

from

Stratagene/Agilent (Cedar Creek, TX). Lysostaphin was purchased from AMBI
Products LLC (Lawrence, NY), and Criterion Tris-HCl gels were purchased from
Bio-Rad (Hercules, CA). Immuno Elution Buffer and BCA assay kit were
obtained from Pierce (Rockford, IL). Protease inhibitors and mouse anti-GFP
antibodies were obtained from Roche (Indianapolis, IN). Mouse anti-HA
antibodies and anti-HA affinity matrix were purchased from Covance
(Emeryville, CA), rabbit anti-Sortase antibodies from Abcam (Cambridge, MA)
and anti-mouse horse radish peroxidase (HRP) and anti-rabbit HRP antibodies
from Bio-Rad (Hercules, CA). ECL and ECL Plus were obtained from Amersham
(Buckinghamshire, UK), and glass slides and coverslips were obtained from
Fisher (Pittsburgh, PA).
Reversed-Phase HPLC and Mass Spectrometry. Analytical and semipreparative
HPLC was performed using a Hewlett-Packard 1100 series instrument with
diode array detection. A Vydac C-18 column (5 μm, 4.6 x 150 mm) with a 1
mL/min flow rate was used for analytical scale HPLC, a Vydac C-18 column (10
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μm, 10 x 250 mm) with a 4 mL/min flow rate was used for semipreparative
HPLC, and a Vydac C-18 column (10 μm, 22 x 250 mm) with an 18 mL/min flow
rate was used for preparative HPLC. A Waters 2795 Separations Module plus 996
photodiode array detector with a Vydac C18 column (3μm, 2.1 x 150 mm) and a
0.2 mL/min flow rate was used for LC-MS. In all cases, linear gradients of 0.1%
aqueous TFA (solvent A) versus 90% acetonitrile, 10% water, and 0.1% TFA
(solvent B) were utilized. ESI-MS was performed on a PE Sciex API-100 single
quadrupole electrospray mass spectrometer. ESI-HRMS was performed on a Q–
TOF Ultima hybrid quadrupole time-of-flight electrospray mass spectrometer
(University of Illinois at Urbana-Champaign Mass Spectrometry Laboratory).
NMR Spectroscopy. Compounds 12-16 were dissolved in CD3-OD or CDCl3, and
1

H and 13C NMR spectra were recorded with a Bruker 400 MHz spectrometer.

Measurements were taken at 298 K, and chemical shift values are relative to
methanol (1H 3.31 ppm, 13C 49.00 ppm) or chloroform (1H 7.26 ppm, 13C 77.16
ppm). Peptides 6-16 were dissolved in DMSO-d6, and 1-D 1H, homonuclear 1H
TOCSY, and ROESY experiments were performed on a Bruker 400 MHz
spectrometer, Bruker 600 MHz spectrometer with cryoprobe, or Bruker Avance
700 MHz spectrometer with cryoprobe, respectively. The mixing times were 77
and 200 ms for TOCSY and ROESY experiments, respectively. In all cases, the
sample temperature was 298 K, and the reported chemical shift values are
relative to DMSO at 2.50 ppm. The chemical shift index (CSI) of each peptide was
calculated using the formula
CSI =  (|ai-6i|)/n
where a is the peptide of interest, 6 is peptide 6, i is the proton type (e.g., Cys1
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NH), and n is the total number of protons included in the calculation. Protons
directly bonded to the macrocyclic scaffold plus the exocyclic N-terminal amide
proton were included in each CSI (Cys1 NH, H, H; Ser2 NH, H; Ser3 NH,
H; Leu NH, H; and Phe NH, H). The protons of the modified residue(s) were
excluded.
Synthesis. 3-t-Butyldisulfanyl-propane-1,2-diol (1). A solution containing 1mercapto-ethane-1,2-diol (3.0 g, 27.7 mmol, 1.0 equiv), 2-methyl-propane-2-thiol
(25 g, 277 mmol, 10.0 equiv), and triethylamine (7.0 g, 69.3 mmol, 2.5 equiv)
dissolved in methanol (55 mL) was stirred at room temperature with bubbling O2
overnight (>10 h). Methanol and excess 2-methyl-propane-2-thiol were removed
in vacuo, and the crude product was purified by flash chromatography using 3:2
hexanes/ethyl acetate to give 5.4 g of 1 (99%) as a clear oil. 1H NMR (400 MHz,
CD3OD)  3.83 (m, 1H),  3.58 (dd, 1H, J = 11.3, 4.8 Hz),  3.52 (dd, 1H, J = 11.3,
5.8 Hz),  2.90 (dd, 1H, J = 13.3, 5.3 Hz),  2.78 (dd, 1H, J = 13.3, 7.3 Hz),  1.34 (s,
9H); 13C NMR (100 MHz, CD3OD)  72.33,  65.90,  48.45,  45.64,  30.25, ESI-MS
m/z calcd for C7H16O2S2 196.3, found 393.0 ([2M + H+]).
In an updated route to 1 in two steps, a solution containing 2-methylpropane-2-thiol (4.5 g, 49.9 mmol, 1.1 equiv), 2,2-dithiodipyridine (10.0 g, 45.4
mmol, 1.0 equiv), and triethylamine (4.6 g, 45.4 mmol, 1.0 equiv), dissolved in
methanol (230 mL) was stirred at room temperature overnight (>10 h). Methanol
and excess 2-methyl-propane-2-thiol were removed in vacuo, and the crude
product was purified by flash chromatography using 1:1 dichlorometane
/methanol to give 9.1 g of 2-(tert-butyldisulfanyl)pyridine (99%). 1H NMR (400
MHz, CDCl3)  8.42 (m, 1H),  7.79 (m, 1H),  7.63 (m, 1H),  7.05 (m, 1H),  1.34
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(s,

9H).

In

the

subsequent

step,

a

solution

containing

2-(tert-

butyldisulfanyl)pyridine (9.1 g, 45.4 mmol, 1.0 equiv), 1-mercapto-ethane-1,2-diol
(5.4 g, 50.2 mmol, 1.2 equiv), and triethylamine (9.3 g, 91.4 mmol, 2.0 equiv),
dissolved in methanol (150 mL) was stirred at room temperature overnight (>10
h). Methanol was removed in vacuo, and the crude product was extracted with
ethyl acetate, washed with 1 N HCl, 1 N NaOH, brine, and dried over Na2SO4,
filtered, and further dried in vacuo. Purification by flash chromatography using
3:2 hexanes/ethyl aectate to give 6.7 g of 1 (75%).
1,2-Bis-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanylbutyldisulfanylpropane (2). t-Butyl-chloro-dimethyl-silane (11 g, 72 mmol, 3.0 equiv), imidazole
(9.8 g, 144 mmol, 6.0 equiv), and 4-dimethylaminopyridine (170 mg, 1.4 mmol,
0.06 equiv) were added on ice to a solution of 1 (4.7 g, 24 mmol, 1.0 equiv)
dissolved in 240 mL of anhydrous DMF. The reaction was stirred under N2 at
room temperature overnight at which point 0.5 N NaOH was added to quench
the reaction, and the product was extracted with ethyl acetate, washed with 1 N
HCl, dried over Na2SO4, filtered, and dried in vacuo. Excess DMF was removed
by an azeotrope with hexanes to yield 10 g (99%) of 2, which was taken on to the
next step without further purification. 1H NMR (400 MHz, CDCl3)  3.89 (m, 1H),

 3.61 (dd, 1H, J = 10.1, 5.0 Hz),  3.53 (dd, 1H, J = 10.1, 6.3 Hz),  2.99 (dd, 1H, J =
13.1, 4.9 Hz),  2.73 (dd, 1H, J = 13.1, 6.7 Hz),  1.33 (s, 9H),  0.90 (s, 18H),  0.08
(m, 12H); 13C NMR (100 MHz, CDCl3)  72.70, 66.40, 47.81, 46.00, 30.06, 26.10,
26.04, 25.86, 25.82, 18.50, 18.30, -2.79, -3.41, -4.39, -4.20, -5.20, -5.18, ESI-MS m/z
calcd for C19H44O2S2Si2 424.2, found 423.0 ([M-]).
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2-(t-Butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propan-1-ol (3). A cold 1:1
mixture of TFA and water (18 mL) was added dropwise to a solution of 2 (4.4 g,
10 mmol, 1.0 equiv) in 45 mL of THF. The reaction was stirred at 0 °C for 4.5 h,
and then it was slowly poured into a separation funnel containing an ice cold
solution of NaHCO3 to bring the pH above 7. The product was extracted with
ethyl acetate, washed with water and brine, dried over Na2SO4, and filtered, and
the solvents were removed in vacuo. Purification by flash chromatography with
15:1 hexanes/ethyl acetate yielded 2.0 g (65%) of 3. 1H NMR (400 MHz, CD3Cl) 
3.97 (m, 1H),  3.70 (dd, 1H, J = 11.3, 3.5 Hz),  3.62 (dd, 1H, J = 11.3, 4.0 Hz), 
2.87 (dd, 1H, J = 13.4, 7.2 Hz),  2.79 (dd, 1H, J = 13.4, 5.4 Hz),  1.34 (s, 9H),  0.91
(s, 9H),  0.13 (s, 3H),  0.10 (s, 3H); 13C NMR (100 MHz, CDCl3)  72.14, 65.01,
48.06, 44.05, 29.98, 25.93, 18.19, -4.29, -4.48, -4.62, ESIMS m/z calcd for
C13H30O2S2Si2 310.2, found 309.0 ([M-]).
2-(t-Butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionaldehyde (4). DessMartin periodinane (1.3 g, 3.1 mmol, 1.2 equiv) was added to a solution of 3 (800
mg, 2.6 mmol, 1.0 equiv) in 26 mL of CH2Cl2 under N2. The reaction was stirred
at room temperature for 2 h, then diluted with CH2Cl2 and ethyl acetate. The
product was washed with 0.1 N HCl, 1 N NaOH, and brine, dried over Na2SO4,
and filtered, and the solvents were removed in vacuo. Purification by flash
chromatography using 19:1 hexanes/ethyl acetate yielded 590 mg (73%) of 4. 1H
NMR (400 MHz, CDCl3)  9.64 (s, 1H),  4.22 (m, 1H),  2.99 (dd, 1H, J = 13.4, 4.2
Hz),  2.80 (dd, 1H, J = 13.4, 7.9 Hz),  1.31 (s, 9H),  0.91 (s, 9H),  0.12 (s, 3H), 
0.10 (s, 3H); 13C NMR (100 MHz, CDCl3)  202.17, 76.57, 48.22, 43.66, 29.97, 25.84,
18.30, -4.55, -4.63, ESI-MS m/z calcd for C13H28O2S2Si 308.1, found 309.0 ([M+H+]).
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2-(t-Butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionic Acid (5).
Compound 4 (227 mg, 0.74 mmol, 1.0 equiv) was dissolved in 4 mL of t-butyl
alcohol. 2-Methyl-2-butene (3.02 g, 42.9 mmol, 58 equiv) was added to the
solution on ice, followed by a pre-dissolved solution of monobasic sodium
phosphate (225 mg, 1.63 mmol, 2.2 equiv) and 80% sodium chlorite (251 mg, 2.22
mmol, 3.0 equiv) in water (4 mL). The reaction was stirred vigorously to ensure
mixing of the two phases at room temperature for 2 h. The reaction mixture was
diluted with ethyl acetate, washed with 0.1 N HCl and brine, dried over Na2SO4,
and filtered, and the solvents were removed in vacuo. Purification by flash
chromatography using 19:1 CH2Cl2/methanol yielded 160 mg (66%) of 5 as a
clear oil. 1H NMR (400 MHz, CDCl3)  4.47 (m, 1H),  3.12 (dd, 1H, J = 13.4, 3.6
Hz),  2.93 (dd, 1H, J = 13.4, 7.9 Hz),  1.33 (s, 9H),  0.92 (s, 9H),  0.15 (s, 3H), 
0.13 (s, 3H); 13C NMR (100 MHz, CDCl3)  176.60, 71.27, 48.23, 45.77, 30.00, 25.82,
18.29, -4.80, -4.86, ESI-HRMS m/z calcd for C13H28O3S2Si [M + H+] 325.1327,
found 325.1329.
Fmoc-SPPS of AIPs. Native AIPs and peptides 6-12, 14, 16, 19, and 20 were
synthesized manually or with a Liberty microwave-assisted automated peptide
synthesizer (CEM). Linker 5 (188 mg, 0.61 mmol, 1.1 equiv relative to resin
substitution) was added to a solution of HBTU (207 mg, 0.55 mmol, 1.0 equiv
relative

to

resin

loading)

in

DMF

(1.2

mL),

followed

by

DIEA

(diisopropylethylamine) (0.25 mL, 1.44 mmol, 2.6 equiv relative to resin) to preactivate the acid. After 3 min, the solution was added to Rink amide resin and
stirred by bubbling N2 through the vessel at room temperature for 4 h.
Remaining free amines were acetylated by two treatments with a 1:1:8 solution of
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acetic anhydride/DIEA/DMF for 10 min. Deprotection of the TBS group was
accomplished by the addition of tetrabutyl ammonium fluoride (10 mL of a 1.0 M
solution in THF) overnight at room temperature. 4-Dimethylaminopyridine (0.1
equiv relative to the C-terminal amino acid) was used in addition to HBTU and
DIEA to double couple the C-terminal amino acid to the hydroxyl group of the
linker. For automated syntheses, the resin was loaded onto the peptide
synthesizer at this point. Subsequent steps were completed with standard
HBTU/DIEA activation and piperidine deprotection protocols for Fmoc solidphase peptide chemistry with a few exceptions. N-Methylated amino acids were
double coupled, once with HBTU and once with HATU. Other unnatural
monomers were coupled with standard methods. Finally, peptides 6–12, 14, and
16 were acetylated at the N-terminus with a 1:1:8 solution of acetic
anhydride/DIEA/DMF for 10 min. Each peptide was cleaved from the solid
support by treatment with 95:2.5:2.5 TFA/TIS/water for 3-4 h at room
temperature, followed by filtration and washing of the beads with the TFA
cleavage cocktail. The peptides were either purified by semipreparative or
preparative HPLC or taken on to the cyclization step without purification.
The cyclization buffer contained 20% acetonitrile and 80% 6 M
guanidinium chloride in 0.1 M sodium phosphate buffer pH 6.5. TCEP (tris-(2carboxy)ethyl phosphine) (70 mM) was added to this solution, and the pH was
brought back up to 6.6-6.8 with 4 M NaOH. Each linear peptide was dissolved in
this solution to a final concentration of 100 μM and rocked at room temperature
for 2-24 h, and the reaction was monitored by analytical HPLC. The desired AIP
product was then purified by semipreparative or preparative HPLC.
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Data for trAIP-II (6). 1H NMR (400 MHz, DMSO-d6)  8.68 (d, 1H, J = 8.8 Hz), 
8.46 (d, 1H, J = 8.2 Hz),  8.12 (m, 2H),  7.60 (d, 1H, J = 8.7 Hz),  7.25 (m, 2H), 
7.21 (m, 3H),  5.12 (t, 1H, J = 5.4 Hz),  5.03 (t, 1H, J = 5.4 Hz),  4.56 (m, 1H), 
4.39 (m, 1H),  4.28 (m, 1H),  4.22 (m, 1H),  3.92 (m, 1H),  3.64 (m, 1H),  3.58
(m, 2H),  3.52 (m, 1H),  3.31 (obsc 1H),  3.16 (m, 1H),  2.84 (m, 2H),  1.86 (s,
3H),  1.38 (m, 1H),  1.30 (m, 1H),  1.22 (m, 1H),  0.74 (d, 3H, J = 6.3 Hz),  0.71
(d, 3H, J = 6.3 Hz), ESI-MS m/z calcd for C26H37N5O8S 579.2, found 580.0 ([M +
H+]). See appendix for chemical shift assignments of peptides 6–16.
Data for S2G (7). 1H NMR (400 MHz, DMSO-d6)  8.67 (d, 1H, J = 9.0 Hz)  8.44
(d, 1H, J = 7.9 Hz),  8.21 (m, 1H),  7.99 (d, 1H, J = 7.7 Hz),  7.59 (d, 1H, J = 8.3
Hz),  7.26 (m, 2H),  7.20 (m, 3H),  5.21 (t, 1H, J = 5.5 Hz),  4.59 (m, 1H),  4.32
(m, 1H),  4.21 (m, 1H),  3.98 (m, 1H),  3.89 (m, 1H),  3.62 (m, 1H),  3.52 (m,
1H),  3.32 (obsc, 1H),  3.31 (obsc, 1H),  3.16 (m, 1H),  2.84 (m, 2H),  1.86 (s,
3H),  1.31 (m, 2H),  1.18 (m, 1H),  0.74 (d, 3H, J = 6.2 Hz),  0.69 (d, 3H, J = 6.2
Hz), ESI-MS m/z calcd for C25H35N5O7S 549.2, found 550.0 ([M+H+]).
Data for S3G (8). 1H NMR (400 MHz, DMSO-d6)  8.46 (m, 1H),  8.36 (d, 1H, J =
7.4 Hz),  8.30 (d, 1H, J = 8.0 Hz),  8.02 (m, 2H),  7.24 (m, 5H),  4.64 (m, 1H), 
4.41 (m, 2H),  3.99 (m, 1H),  3.79 (dd, 1H, J = 14.0, 3.6 Hz),  3.57 (m, 3H),  3.35
(obsc, 1H),  3.13 (m, 1H),  2.91 (m, 1H),  2.62 (m, 1H),  1.86 (s, 3H),  1.49 (m,
1H),  1.12 (m, 2H),  0.78 (d, 3H, J = 6.5 Hz),  0.71 (d, 3H, J = 6.5 Hz); ESI-MS
m/z calcd for C25H35N5O7S 549.2, found 550.0 ([M+H+]).
Data for GG (9). 1H NMR (400 MHz, DMSO-d6)  8.39 (m, 1H)  8.29 (m, 2H), 
8.15 (d, 1H, J = 9.4 Hz),  8.08 (m, 1H),  7.23 (m, 5H),  4.67 (m, 1H),  4.42 (m,
1H),  4.10 (m, 1H),  3.98 (m, 1H),  3.79 (m, 1H),  3.58 (dd, 1H, J = 14.2, 6.4 Hz),
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 3.28 (obsc, 1H),  3.18 (m, 1H),  2.87 (m, 1H),  2.72 (m, 1H),  1.86 (s, 3H), 
1.43 (m, 2H),  1.10 (m, 1H),  0.78 (d, 3H, J = 6.5 Hz),  0.71 (d, 3H, J = 6.5 Hz);
ESI-MS m/z calcd for C24H33N5O6S 519.2, found 520.3 ([M+H+]).
Data for N-MeS2 (10). 1H NMR (400 MHz, DMSO-d6)  8.73 (d, 1H, J = 8.3 Hz), 
8.56 (d, 1H J = 9.0 Hz),  7.98 (d, 1H J = 7.4 Hz),  7.49 (d, 1H, J = 8.1 Hz),  7.25
(m, 2H),  7.18 (m, 3H),  5.25 (m, 1H),  4.95 (m, 3H),  4.38 (m, 1H),  4.16 (m,
1H),  4.08 (m, 1H),  3.80 (m, 1H),  3.73 (m, 2H),  3.33 (obsc, 1H),  3.12 (m,
1H),  3.00 (s, 3H),  2.90 (m, 1H),  2.83 (m, 1H),  1.87 (s, 3H),  1.26 (m, 3H), 
0.73 (m, 6H); ESI-MS m/z calcd for C27H39N5O8S 593.3, found 595.0 ([M+H+]).
Data for N-MeS3 (11a and 11b). (cis and trans amide isomers ~50% each): 1H
NMR (400 MHz, DMSO-d6)  8.66 (d, 1H, J = 7.4 Hz),  8.47 (d, 1H, J = 7.6 Hz), 
8.24 (d, 1H, J = 8.6 Hz),  8.10 (m, 3H),  7.48 (m, 2H),  7.25 (m, 5H),  7.14 (m,
5H),  4.90 (m, 1H),  4.83 (m, 1H),  4.59 (m, 1H),  4.51 (m, 1H),  4.45 (m, 1H), 
4.35 (m, 1H),  4.26 (m, 1H),  4.12 (m, 2H),  3.99 (m, 1H),  3.88 (m, 1H),  3.77
(m, 1H),  3.63 (m, 1H),  3.56 (m, 3H),  3.34 (obsc, 1H),  3.29 (obsc, 1H),  3.26
(obsc, 1H),  3.24 (obsc, 1H),  3.14 (m, 2H),  3.02 (m, 1H),  2.97 (m, 2H),  2.66
(s, 6H),  2.49 (obsc, 1H),  1.86 (s, 6H),  1.39 (m, 5H),  1.29 (m, 1H),  0.77 (m,
6H),  0.73 (m, 6H); ESI-MS m/z calcd for C27H39N5O8S 593.3, found 595.0
([M+H+]).
Data for N-MeL (12). 1H NMR (400 MHz, DMSO-d6)  8.45 (d, 1H, J = 8.2 Hz), 
8.25 (d, 1H, J = 9.9 Hz),  8.05 (d, 1H, J = 8.5 Hz),  7.76 (d, 1H, J = 9.1 Hz),  7.25
(m, 3H),  7.21 (m, 2H),  5.15 (m, 1H),  4.82 (m, 1H),  4.75 (m, 1H),  4.67 (m,
1H),  4.44 (m, 1H),  4.22 (m, 1H),  3.63 (m, 2H),  3.50 (m, 1H),  3.45 (m, 1H), 
3.37 (obsc, 1H),  3.36 (obsc, 1H),  3.11 (m, 1H),  3.01 (s, 3H),  2.89 (m, 1H), 
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2.70 (m, 1H),  1.90 (m, 1H),  1.85 (s, 3H),  1.37 (m, 1H),  1.25 (m, 1H),  0.75 (d,
3H, J = 6.5 Hz),  0.69 (d, 3H, J = 6.4 Hz); ESI-MS m/z calcd for C27H39N5O8S 593.3,
found 595.0 ([M+H+]).
Data for Meth Link (14). 1H NMR (400 MHz, DMSO-d6)  8.24 (d, 1H, J = 7.8 Hz),
 8.09 (m, 1H),  7.94 (d, 1H, J = 8.9 Hz),  7.74 (d, 1H, J = 9.2 Hz),  7.26 (m, 3H), 
7.20 (m, 2H),  4.67 (m, 1H),  4.34 (m, 1H),  4.20 (m, 1H),  3.43 (m, 1H),  3.28
(obsc, 1H),  3.21 (obsc, 1H),  2.90 (m, 1H),  2.76 (m, 2H),  2.11 (m, 1H),  2.01
(m, 1H),  1.84 (s, 3H),  1.50 (m, 3H),  1.32 (m, 1H),  1.20 (m, 2H),  0.97 (m,
1H),  0.75 (d, 3H, J = 6.5 Hz),  0.68 (d, 3H, J = 6.5 Hz); ESI-MS m/z calcd for
C25H36N4O5S 504.2, found 505.0 ([M+H+]).
Data for  N-term (16). 1H NMR (400 MHz, DMSO-d6)  8.76 (d, 1H, J = 8.4 Hz), 
8.18 (d, 1H, J = 7.5 Hz),  8.06 (d, 1H, J = 7.8 Hz),  7.34 (d, 1H, J = 8.7 Hz),  7.26
(m, 3H),  7.20 (m, 2H),  5.09 (t, 1H, J = 5.0 Hz),  4.98 (t, 1H, J = 5.3 Hz),  4.54
(m, 1H),  4.26 (m, 1H),  4.18 (m, 1H),  3.88 (m, 1H),  3.64 (m, 4H),  3.33 (obsc,
1H),  3.21 (m, 1H),  2.85 (m, 2H),  2.62 (obsc, 1H),  2.34 (m, 1H),  1.42 (m, 1H),
 1.24 (m, 2H),  0.74 (d, 3H, J = 6.3 Hz),  0.70 (d, 3H, J = 6.3 Hz); ESI-MS m/z
calcd for C24H34N4O7S 522.2, found 523.0 ([M+H+]).
Data for AIP-I M8pMet-Biotin (19). ESI-MS m/z calcd for C54H74N12O15S2 1195.4,
found 1195.9 ([M+H+]).
Data for AIP-I M8pMet (20). ESI-MS m/z calcd for C44H60N10O13S 969.1, found
969.9 ([M+H+]).
trAIP-II Lactam (15) Synthesis. The peptide was synthesized similarly to the
full-length AIP-II lactam (19). Chain elongation was completed using Fmoc-SPPS
protocols. Fmoc-Serine(benzyl)-OH was used in residue positions two and three.
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Fmoc-DAPA(Boc)-OH was used in place of cysteine in position one. Once
cleaved from the resin with TFA, the partially protected linear peptide was
cyclized with PyBop and DIEA, purified by semipreparative HPLC, and treated
with 25:1 HF:4-methyl-phenol (p-cresol) for 1 h at 0 oC to remove the benzyl
groups. The final product was purified with semipreparative HPLC. 1H NMR
(400 MHz, DMSO-d6)  8.67 (m, 1H),  8.11 (m, 1H),  8.04 (m, 1H),  7.72 (m, 1H),
 7.59 (m, 1H),  7.49 (m, 1H),  7.20 (m, 5H),  4.38 (m, 2H),  4.31 (m, 1H),  3.94
(m, 1H),  3.84 (m, 1H),  3.79 (m, 1H),  3.71 (m, 1H),  3.62 (m, 3H),  3.21 (obsc,
1H),  3.00 (m, 1H),  2.85 (m, 1H),  1.84 (s, 3H),  1.37 (m, 1H),  1.25 (m, 1H), 
1.10 (m, 1H),  0.76 (d, 3H, J = 6.5 Hz),  0.69 (d, 3H, J = 6.2 Hz); ESI-MS m/z calcd
for C26H38N6O8S 562.3, found 563.5 ([M+H+]).
Boc-SPPS of AIPs. AIP-II N3A, L8A, F9A, F9Nal, native AIPs, and peptides 13,
17, and 18 were manually synthesized. Manual solid phase peptide synthesis
with standard in situ neutralization/HBTU activation protocol for Boc chemistry
(82) was used for chain elongation on a mercaptopropionamide MBHA resin.
Leucine was double-coupled to N-methylated phenylalanine with HBTU, then
HATU. Peptides were cleaved from the resin by treatment with 25:1 HF:p-cresol
for 1 h at 0 oC, precipitated and washed with diethyl ether, and purified by
semipreparative or preparative HPLC. After lyophilization, the linear peptides
were dissolved again in MeCN, water, and 0.1% TFA and cyclized in solution by
the addition of 4x volume of 0.1 M sodium phosphate buffer, pH 7, for 2 h at
room temperature. The final products were purified by semipreparative or
preparative HPLC.
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Data for AIP-II N3A. ESI-MS m/z calcd for C37H57N9O11S 836.0, found 836.9
([M+H+]).
Data for AIP-II L8A. ESI-MS m/z calcd for C35H52N10O12S 836.9, found 837.9
([M+H+]).
Data for AIP-II F9A. ESI-MS m/z calcd for C32H54N10O12S 802.9, found 803.9
([M+H+]).
Data for AIP-II F9Nal. ESI-MS m/z calcd for C42H60N10O12S 929.1, found 929.9
([M+H+]).
Data for N-MeF (13). 1H NMR (400 MHz, DMSO-d6)  8.50 (d, 1H, J = 8.3 Hz), 
8.25 (d, 1H, J = 8.6 Hz),  7.86 (d, 1H, J = 9.2 Hz),  7.80 (d, 1H, J = 9.1 Hz),  7.25 (m,
3H),  7.14 (m, 2H),  5.16 (m, 1H),  5.00 (m, 1H),  4.63 (m, 1H),  4.39 (m, 1H), 
4.28 (m, 1H),  4.25 (m, 1H),  4.20 (m, 1H),  3.63 (m, 1H),  3.53 (m, 3H),  3.21
(obsc, 2H),  3.19 (obsc, 1H),  2.89 (m, 1H),  2.64 (s, 3H),  1.88 (s, 3H),  1.52 (m,
2H),  1.32 (m, 1H),  0.86 (d, 3H, J = 6.0 Hz),  0.81 (d, 1H, J = 6.1 Hz); ESI-MS m/z
calcd for C27H39N5O8S 593.3, found 595.0 ([M+H+]).
Data for AIP-II Bpa-Biotin (17). ESI-MS m/z calcd for C64H85N13O16S2 1356.6,
found 1357.9 ([M+H+]).
Data for AIP-II Bpa (18). ESI-MS m/z calcd for C54H71N11O14S 1130.3, found 1131.6
([M+H+]).
(S)-4-methyl 1-perfluorophenyl 2-(tert-butoxycarbonylamino)succinate (21).
Boc-Glu(OMe)-OH.DCHA (5.0 g, 11.3 mmol, 1.0 equiv) was added to 1.5 M
H2SO4 (9 mL), extracted with ethyl acetate (35 mL), washed with H2O, dried over
Na2SO4, filtered, and solvent was removed in vacuo to give 3.0 g Boc-Glu(OMe)OH (99%) as a yellow oil. Boc-Glu(OMe)-OH (3.0 g, 11.3 mmol, 1.0 equiv) was
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next dissolved in DMF (76 mL) and pyridine (1.10 mL, 13.7 mmol, 1.2 equiv)
under Ar. Pentafluorophenyl trifluoroacetate (2.46 mL, 14.3 mmol, 1.25 equiv)
was added slowly, the reaction was stirred at room temperature 1 h, then diluted
with ethyl acetate. The product was washed with 1 N HCl, NaHCO3, H2O, and
brine, dried over Na2SO4, filtered, and the solvent was removed in vacuo to give
4.6 g of 21 as a yellow oil (94%). The product was taken onto the next step
without further purification.
(S)-5-methyl

1-perfluorophenyl

2-(tert-butoxycarbonylamino)pentanedioate

(22). Boc-Asp(OMe)-OH (3.7 g, 14.9 mmol, 1.0 equiv) was next dissolved in DMF
(65 mL) and pyridine (1.44 mL, 17.8 mmol, 1.2 equiv) under Ar.
Pentafluorophenyl trifluoroacetate (3.2 mL, 18.6 mmol, 1.25 equiv) was added
slowly, the reaction was stirred at room temperature 1 h, then diluted with ethyl
acetate. The product was washed with 1 N HCl, NaHCO3, H2O, and brine, dried
over MgSO4, filtered, and the solvent was removed in vacuo to give 4.9 g of 22 as
a yellow oil (79%). The product was taken onto the next step without further
purification.
(S)-methyl 5-(3-bromopropylamino)-4-(tert-butoxycarbonylamino)-5-oxopentanoate (23). A solution of 21 (4.6 g, 10.7 mmol, 1.2 equiv) dissolved in DIEA (1.86
mL, 10.7 mmol, 1.2 equiv) and DMF (24 mL) was stirred at room temperature 30
min under Ar. A solution of 3-bromopropyl ammonium bromide (1.95 g, 8.9
mmol, 1.0 equiv) in DIEA (1.55 mL, 8.9 mmol, 1.0 equiv) and DMF (8 mL) was
added to the reaction mixture, which was stirred at room temperature 5 h,
diluted with ethyl acetate, washed with H2O, dried over Na2SO4, filtered, and the
solvent was removed in vacuo. The product was purified by flash
chromatography using 2:5 ethyl acetate/hexanes to give 1.8 g of 23 (52%).
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(S)-methyl 5-(3-azidopropylamino)-4-(tert-butoxycarbonylamino)-5-oxopentanoate (24). (This step was completed by Matthew Pratt.) Bromide 23 (1 g, 2.6
mmol, 1.0 equiv) was dissolved in DMF (20 mL) and the mixture was heated to
45 °C. NaN3 (660 mg, 13.1 mmol, 5.0 equiv) was added, and the reaction was
stirred for 16 h. At this time, the reaction was cooled to room temperature,
diluted with ethyl acetate (100 mL) and washed with H2O (50 mL) two times.
The organic layer was dried over Na2SO4, filtered, and concentrated. Silica gel
chromatography (50% ethyl acetate in hexanes) yielded 620 mg of 24 (70%) as a
clear oil. The reaction was repeated to give 1.3 g of 24 for the next step.
(S)-methyl 5-(3-azidopropylamino)-4-((S)-2-(tert-butoxycarbonylamino)-4methoxy-4-oxobutanamido)-5-oxopentanoate (25). A solution of 24 (1.3 g, 3.82
mmol, 1.0 equiv) in 95:5 TFA/H2O (21 mL) was stirred at room temperature 1 h.
The solvent was removed by azeotrope with toluene, and the product ((S)methyl 4-amino-5-(3-azidopropylamino)-5-oxopentanoate, 928 mg, 3.82 mmol,
1.0 equiv), was then added to a solution of 22 (1.9 g, 4.43 mmol, 1.2 equiv) in
DIEA (664 μL, 3.82 mmol, 1.0 equiv) and DMF (13 mL). The reaction was stirred
at room temperature 21 h, diluted with ethyl acetate, washed with 1 N HCl,
NaHCO3, H2O, and brine, dried over MgSO4, filtered, and the solvent was
removed in vacuo. The product was purified by flash chromatography using 4:1
ethyl acetate/hexanes to give 406 mg of 25 (23%) as a clear oil.
(2S,3S)-2-ethyl 3-perfluorophenyl oxirane-2,3-dicarboxylate. (This step was
completed

by

Matthew

Pratt.)

First,

the

epoxide,

(2S,3S)-3-

(ethoxycarbonyl)oxirane-2-carboxylic acid, was synthesized by the route
reported by Meara et al. (126). This expoxide (1 g, 6.25 mmol) was dissolved in
DMF (20 mL) and pyridine (560 uL, 6.88 mmol) under an inert atmosphere.
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Pentafluorophenyl trifluoroacetate (1.24 mL, 7.19 mmol) was then added slowly,
and the reaction was stirred for 16 h. Dilution with ethyl acetate (50 mL) was
followed by washes with 1 N HCl, H2O, and brine. The organic layer was dried
over Na2SO4, filtered, and concentrated. The resulting pink solid was used in the
next reaction without further purification.
(2R,3R)-ethyl 3-((S)-1-((S)-1-(3-azidopropylamino)-5-methoxy-1,5-dioxopentan2-ylamino)-4-methoxy-1,4-dioxobutan-2-ylcarbamoyl)oxirane-2-carboxylate
(26). A solution of 25 (100 mg, 0.212 mmol, 1.0 equiv) in 95:5 TFA/H2O (18 mL)
was stirred at room temperature 1 h. The solvent was removed by azeotrope
with toluene, and the product, ((S)-methyl 4-((S)-2-amino-4-methoxy-4-oxobutanamido)-5-(3-azidopropylamino)-5-oxopentanoate, 79 mg, 0.212 mmol, 1.0
equiv), was then added to a solution of (2S,3S)-2-ethyl 3-perfluorophenyl
oxirane-2,3-dicarboxylate (83 mg, 0.254 mmol, 1.2 equiv) in DIEA (37 μL, 0.212
mmol, 1.0 equiv) and DMF (4.5 mL). The reaction was stirred at room
temperature 19 h, diluted with ethyl acetate, washed with 1 N HCl, NaHCO3,
H2O, and brine, dried over MgSO4, filtered, and the solvent was removed in
vacuo. The product was purified by flash chromatography using 15% hexanes in
ethyl acetate to give 52 mg of 26 (48%) as a white solid. 1H-NMR (100 MHz,
CDCl3)  7.58 (d, 1H, J = 7.2 Hz),  7.07 (d, 1H, J = 7.9 Hz),  6.73-6.70 (m, 1H), 
4.72 (q, 1H, J = 6.0 Hz),  4.38-4.33 (m, 1H),  4.32-4.23 (m, 2H),  3.89 (s, 1H), 
3.73 (m, 7H),  3.34 (m, 4H),  3.05 (dd, 1H, J = 17.2, 4.3 Hz),  2.79 (dd, 1H, J =
17.3, 6.1 Hz),  2.59 (m, 1H),  2.46-2.39 (m, 1H),  2.14-2.08 (m, 2H),  1.81-1.78
(m, 2H),  1.32 (t, 3H J = 7.1 Hz); 13C-NMR (101 MHz, CDCl3)  175.30, 172.13,
171.04, 170.29, 167.06, 166.96, 62.72, 54.17, 53.80, 53.04, 52.66, 52.55, 49.84, 49.45,
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37.40, 36.11, 30.70, 28.91, 26.75, 14.43; ESI-MS m/z calcd for C20H30N6O10 514.5,
found 537.0 ([M+Na+]) and 515.0 ([M+H+]).
AgrB Inhibition Assay. Cultures of strains RN7206 (agr null) and RN6734 (agr
group I) were grown to early exponential phase, pelletted and washed with
media, and the supernatants were discarded. The cultures were re-suspended in
media containing 0.5 nM–100 μM compound 26 or only DMSO vehicle and
grown 1 h. Cells were pelleted, and the supernatants were recovered, filtered,
and tested for AIP activity in the reporter assay. The cell pellets were then resuspended in media containing 0.5 nM–100 μM compound 26 or only DMSO
vehicle a second time and grown for 40 min. The supernatants were recovered
and tested for activity as in the first test.
Reporter Assays. AIP activities were analyzed using a previously described
method with a -lactamase reporter gene read-out (52). Strains RN9222, RN9372
containing plasmid-borne agrC and P3-blaZ (assays performed in Chapters 2 &
4), or derivatives of RN10829 containing plasmid-borne agrC and chromosomal
P3-blaZ (assays performed in Chapter 3) were grown to mid-exponential phase
and transferred to microtiter plates. In experiments involving constitutive
mutants, growth proceeded without transfer to microtiter plates. 80 μL aliquots
were treated in duplicate with synthetic AIPs or supernatants for 1 h with
shaking at 37 oC in a THERMOmax microplate reader (Molecular Devices). Cell
density was monitored by OD650 readings taken every 1 min. Immediately
following Nitrocefin addition, hydrolysis was monitored by OD490 readings taken
every 20 seconds over 20 min. All peptide stock solution concentrations were
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determined by amino acid analysis (AAA) at the Keck AAA and Protein
Sequencing Lab (Yale University, New Haven, CT).
Assay data were normalized to percent maximal activation and plotted as
initial -lactamase reaction velocity versus log peptide concentration. PRISM 4.0
(GraphPad, San Diego) was used to fit individual agonist or antagonist doseresponse curves via nonlinear regression to the following four-parameter logistic
equation:

E = basal +

E max  basal
1+ 10 log EC50 log[A]n H

in which E denotes effect, [A] denotes the agonist concentration, nH denotes the
midpoint slope, EC50 denotes the midpoint location parameter, and Emax and
basal denote the upper and lower asymptotes, respectively. For inhibition curves,
the midpoint location parameter from the above equation reflects the IC50. Each
data point represents two or three replicates, and error bars represent standard
error measurements. All curves shown in the same graph correspond to
experiments performed on the same day.
Bacterial Strains and Growth Conditions. The S. aureus strains used in this
study (Table 7) are derivatives of NCTC8325. RN7206 is a derivative of the
standard agr group I laboratory strain, RN6734, in which the agr locus has been
replaced by tetM. Cloning was performed using E. coli strain DH5. All clones
were first transformed into RN4220, the standard recipient for E. coli DNA,
before transduction to other strains. S. aureus cells from overnight plates
containing the appropriate selective antibiotics (chloramphenicol, 10 mg/ml
and/or erythromycin, 10 mg/ml) were used as inocula for all experiments.
Subsequent growth in CYGP or MH broth without antibiotics was performed at
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Table 7. Strains and Plasmids Used in this Study.
Strain or
Plasmid
S. aureus strains
RN4220
RN6734
RN7206
RN9222

RN9372

RN10828
RN10829

EG61
E. coli strains
DH5
XL1-Blue
Plasmids
pRN9256
pRN9231
pEG54
pRN9232
pEG55
pEG58
pEG59
pEG60
pEG61
pEG62
pEG63
pEG64
pEG65
pEG66
pEG67
pEG68
pEG69
pEG70
pEG71
pEG72

Genotype or Description

Reference

Restriction-deficient mutant of strain 8325-4
Standard agr-I laboratory strain
agr::tetM replacement in RN6734
RN6911 (agr::tetM replacement in agr-I strain)
containing pRN7062 (P2-agrCA-I; P3-blaZ) (Group I
-lactamase reporter strain)
RN9120 (agr::tetM replacement in agr-II strain)
containing pRN7035 (P2-agrCA-II; P3-blaZ) (Group II
-lactamase reporter strain)
RN7206 containing pRN9253 (P2-agrBDA; P3RNAIII) integrated into the SaPI1 att site (hemolysis
assay strain)
RN7206 containing pRN9254 (P2-agrA; P3-blaZ)
integrated into the SaPI1 att site (-lactamase reporter
strain)
RN7206 containing pRN9256 (P2-agrBD; P3-RNAIII)
integrated into the SaPI1 att site ( agrA strain)

(127)
(13)
(13)
(40)

Standard recipient for plasmid cloning
Supercompetent cells

Promega
Stratagene

Shuttle/suicide vector pJC1111 (58) containing SaPI1
integration cassette and agrA construct (P2-agrBD;
P3-RNAIII)
Shuttle vector with promoter P2, insertion site for
agrC, P2 terminator, pT181 replicon, and Em marker
pRN9231 containing replacements by pC194 replicon
and Cm marker
pRN9231 with agrC-I
pEG54 with agrC-I
pRN9231 with agrC-IKin (G394A,G396A) -HA
pEG54 with agrC-IHis (H239Q) -PKA
pRN9231 with agrC-I G394A
pRN9231 with agrC-I G396A
pRN9231 with agrC-I N339D
pRN9231 with agrC-I-gfp
pRN9231 with agrC-IKin-gfp
pEG54 with agrC-IHis-gfp
pRN9231 with agrC-I 1-204
pRN9231 with agrC-I 1-175
pRN9231 with agrC-I 35-175
pRN9231 with agrC-I 1-135
pRN9231 with agrC-I 1-72
pRN9231 with agrC-IKin 1-204
pRN9231 with agrC-IKin 1-175

This work
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(40)

(58)
(58)

This work

(58)
This work
(58)
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work

Table 7. (continued)
pEG73
pEG74
pEG75
pEG78
pEG79
pEG80
pEG81
pEG82
pRN9248
pEG83
pEG84
pEG85
pEG86
pEG87
pEG88
pEG89
pEG90
pEG97
pEG99
pEG100

pRN9231 with agrC-IKin 35-175
pRN9231 with agrC-IKin 1-135
pRN9231 with agrC-IKin 1-72
pRN9231 with agrC-I 1-204-gfp
pRN9231 with agrC-I 1-175-gfp
pRN9231 with agrC-I 35-175-gfp
pRN9231 with agrC-I 1-135-gfp
pRN9231 with agrC-I 1-72-gfp
pRN9231 with agrC-ISensor (T104V, S107V, S116I)
pRN9231 with agrC-ISensor, Kin
pEG54 with agrC-ISensor, His
pRN9231 with agrC-ISensor-gfp
pRN9231 with agrC-I R238H (42)
pRN9231 with agrC-IKin R238H
pEG54 with agrC-IHis R238H
pRN9231 with agrC-I R238H-gfp
pEG54 with agrC-I R238H-HA
pRN9231 with agrC-II
pEG54 with agrC-IIHis
pRN9231 with agrC-IIKin
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This work
This work
This work
This work
This work
This work
This work
This work
(58)
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work

37 °C with shaking. Cell density was determined using a THERMOMax
microplate reader (Molecular Devices) to measure the OD650 of 100 μL culture
samples.
Plasmid and Reporter Construction. The plasmids used in this study (Table 7)
were prepared by cloning PCR products obtained from oligonucleotide primers
(Table 8). Clones were sequenced by the Skirball DNA Sequencing Core Facility
or Genewiz. Plasmid pRN9231 was used as the backbone vector for WT agrC and
G-box mutant constructs and contains the agrP2 promoter, an erythromycin
resistance cassette, and the pT181 replicon (58). Compatible plasmid pEG54,
which served as the backbone vector for H-box mutant agrC constructs, was
created by replacing the resistance cassette and replicon of pRN9231 with a
chloramphenicol resistance cassette and the pC194 replicon, cloned with ApaI
and NarI sites. These plasmids contain an insertion site for agrC, formed by PstI
and KpnI restriction sites, such that agrC expression is driven by agrP2. Point
mutations in agrC were introduced via QuikChange (Stratagene) or by two-step
PCR. agrC truncation and deletion mutants were constructed by inverse PCR on
pUC18 subclones, closing on silent AflII or BglII sites. A C-terminal AgrC
translational fusion to GFP was constructed using an in-frame XbaI site, and
subsequent

GFP-tagged

mutants

were

created

either

by

site-directed

mutagenesis as above or using a ClaI site endogenous to agrC to swap in the
mutant sequences. A chromosomal agr locus derivative lacking agrC, B, and D
was constructed by deleting agrB and D from pRN9254.
Fluorescence Microscopy. Cultures were grown to high optical density (OD650
>0.5), pelleted, and re-suspended in PBS, concentrating the cells up to 50-fold
relative to the liquid culture density. 5 mL aliquots of cells were added to # 1.5
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Table 8. Oligonucleotide Primers Used in this Study.
Primer

Sequence (5’ – 3’)*

AgrC-I-F
KpnI-R
H239Q-F
H239Q-R
G394A-F
G394A-R
G396A-F
G396A-R
G394, 6A-F
G394, 6A-R
N339D-F
N339D-R
 1-175-F
 35-175-F
 35-175-R
 1-135-F
 1-72-F
aflII-R
AgrCI-I
H239Q-R
AgrC-IIH239Q-F
AgrC-I-GFPXba-R
AgrC-I-GFPKpn-F
R238H,
H239Q-R

CCAGCTGCAGGAAGTACCAAAAGAATTAACACAA
GAGCTCGGTACCTTCATACATTCACATCCTTATGGCTAGTTG
GCGCAAGTTCCGTCAGGATTATGTCAATATC
GATATTGACATAATCCTGACGGAACTTGCGC
GGTGAAGGTCGTGCTTTAGGTCTATCAAC
GTTGATAGACCTAAAGCACGACCTTCACC
GGTGAAGGTCGTGGTTTAGCTCTATCAAC
GTTGATAGAGCTAAACCACGACCTTCACC
GGTGAAGGTCGTGCTTTAGCTCTATCAAC
GTTGATAGAGCTAAAGCACGACCTTCACC
GGTATTATTCTTGATGATGCAATTGAGGCATC
GATGCCTCAATTGCATCATCAAGAATAATACC
ACTCGCTTAAGGCTAAAGTAATAAGGCAGTATTC
ACTCGCTCGAGGCTAAAGTAATAAGGCAGTATTC
AATACTCGAGTTTACTGTACTTAATACCACTAATTATAGCTG
GAGTTCTTAAGAAAATTAGCACACCATATCTAATAC
ATTTTCTTAAGATCAAATGGTATTCTATTTTGTTG
TAACTATTTAACTTAAGCACCTACTATCACACTCTC

XmaI-F
R238H-HA-F
R238H-HA-R
R238H-GFP-F
R238H-GFP-R

RE
site
used
PstI
KpnI

Afl-II
XhoI
XhoI
AflII
AflII
AflII

GACATAATCCTGACGGAACTTGCGCATTTCATTATTAATTG
GCGCAAGTTCCGTCAGGATTATGTCAATATCTTAACGACAC
CTTATCTAGAATTGTTAATAATTTCAACTTTTTGAATAAAGAAAC
C
TAAGGGTACCTGCAGAAGTACCAAAAGAATTAACACAATTACA
CG
GTAGCCCGGGCATGTCATCTTCTCGAATGTATTCTGAAAGTGTC
GTTAAGATATTGACATAATCCTGATGGAACTTGCGCATTTCGTTG
TTG
GACATGCCCGGGCTACGTGATTATTTCAATAAAAATATTGTACC
GCGCAAGTTCCATCATGATTATGTCAATATC
GATATTGACATAATCATGATGGAACTTGCGC
GCGCAAGTTCCATCATGATTATGTC
GACATAATCATGATGGAACTTGCGC

XbaI
PstI,
KpnI
XmaI
XmaI

Restriction sites are underlined. Overlapping restriction sites in AgrC-I-GFPKpn-F are underlined (KpnI) and italicized (Pst1).
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coverslips that were previously coated with poly-lysine solution and placed on
glass slides. Imaging was immediately carried out on a DeltaVision image
restoration microscope (Applied Precision/Olympus). Images were deconvolved
with SoftWoRx (Applied Precision).
Western Blotting. Cultures were grown to high optical density (OD650 >0.5),
pelleted, and washed with buffer containing 10mM Tris-HCl, pH 7.4, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, and 1.1 M sucrose (wash buffer). Cells
were lysed by treatment with 100 μg/mL lysostaphin in wash buffer containing
protease inhibitors, followed by rocking for 10 min at 37 oC, high speed spin (30
min, 8,000g), removal of supernatant, and resuspension in lysis buffer (50 mM
Tris-HCl, pH 7.4, 0.5% NP-40, 5 mM MgCl2; or 50 mM Tris-HCl, pH 7.4, 1.0% NP40, 0.25% DOC, 150 mM NaCl, and 1 mM EGTA) containing 10 μg/mL DNase
and protease inhibitors. Lysates were incubated on ice 10 min, and the soluble
fractions were removed following 30 min spin at 10,000g. Total protein
concentrations of the soluble fractions were determined by BCA assay. SDS
loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 1 mg/mL bromophenol blue,
10% glycerol) was added to samples, which were then untreated or acidified
with Immuno Elution buffer (Pierce) prior to loading on 10-20% Criterion TrisHCl gel. Protein transfer to nitrocellulose membrane was followed by
immunoblotting with mouse anti-GFP, mouse anti-HA, or rabbit anti-Sortase
primary antibodies and anti-mouse HRP or anti-rabbit HRP secondary
antibodies. Visualization was carried out with ECL or ECL Plus.
Immunoprecipitation. Cultures of derivatives of RN10306 containing GFP
and/or HA-tagged AgrC were grown to high optical density (OD650 >0.5). Each

136

culture was split into two subcultures, one treated with 1 uM AIP-I and one with
buffer. All subcultures were grown for an additional 15 minutes. Cells were then
pelleted, washed, and lysed, as for western blotting. 250 μg aliquots of total
protein, diluted with lysis buffer to uniform final volumes, were added to 25 μL
aliquots of anti-HA affinity matrix washed with lysis buffer. Samples were
incubated 1 h at 4 ªC, with mixing by slow rotation. Unbound material was
removed following centrifugation. Beads were washed gently three times with
lysis buffer, and bound proteins were eluted with Immuno Elution buffer
(Pierce) by gentle mixing for three minutes. Analysis of samples was completed
by western blot, as above.
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Appendix: NMR Chemical Shift Assignments of trAIP-II and Derivatives.

AIP

H
H
Derivative
NH
Other
6 trAIP-II
Cys
8.46
4.39
3.16, 2.85
Ser
8.11
4.22
3.64, 3.52
5.03
Ser
7.60
4.28
3.58
5.12
Leu
8.13
3.92
1.38, 1.30
1.22
0.74, 0.71
Phe
8.68
4.56
3.31, 2.83
7.25, 7.21
Ac
1.86
7 S2G
Cys
8.44
4.32
3.16, 2.87
Gly
8.21
3.89, 3.52
Ser
7.59
4.21
3.62, 3.32
5.21
Leu
7.99
3.98
1.31
1.18
0.74, 0.69
Phe
8.67
4.59
3.31, 2.81
7.26, 7.20
Ac
1.86
8 S3G
Cys
8.30
4.44
3.13, 2.62
Ser
7.99
4.39
3.57
4.94
Gly
8.46
3.79, 3.58
Leu
8.36
3.99
1.12
1.49
0.78, 0.71
Phe
8.02
4.64
3.35, 2.91
7.24, 7.20
Ac
1.86
9 GG
Cys
8.30
4.42
3.18, 2.72
Gly
8.39
4.10, 3.29
Gly
8.08
3.79, 3.58
Leu
8.28
3.98
1.43
1.10
0.78, 0.71
Phe
8.15
4.67
3.28, 2.87
7.26, 7.22
Ac
1.86
10 N-MeS2
Cys
8.56
5.00
3.12, 2.83
N-MeSer
4.14
3.79
OH 4.92, Me 3.01
Ser
7.49
4.95
3.73
5.25
Leu
7.98
4.08
1.26
1.15
0.73
Phe
8.73
4.38
3.33, 2.90
7.25, 7.19
Ac
1.87
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NMR Chemical Shift Assignments (continued).

11a N-MeS3
(trans)
Cys
Ser
N-MeSer
Leu
Phe
Ac
11b N-MeS3
(cis)
Cys
Ser
N-MeSer
Leu
Phe
Ac
12 N-MeL
Cys
Ser
Ser
N-MeLeu
Phe
Ac
13 N-MeF
Cys
Ser
Ser
Leu
N-MePhe
Ac
14 Meth
Link
Cys
Pent
Leu
Phe
Ac

NH



H

8.47
8.11

4.12
4.90
4.11
4.35
4.26

3.13, 2.96
3.57, 3.26
3.77, 3.63
1.41, 1.34
3.24, 2.97

4.45
4.83
4.51
3.99
4.59

3.15, 2.49
3.56, 3.34
3.88, 3.55
1.35
3.29, 3.02

8.25

4.44
4.22
4.67
3.45
4.75

3.11, 2.89
3.63, 3.50
3.63, 3.36
1.90, 1.37
3.37, 2.70

8.50
8.25
7.80
7.86

4.39
4.20
4.28
4.63

3.19, 2.89
3.55
3.63, 3.51
1.52

4.25

3.21

4.34
3.43, 2.73
4.20
4.67

3.21, 2.90
2.11, 2.01
1.25, 1.14
3.28, 2.79

7.48
8.66

8.24
8.09
7.48
8.08

8.45
8.05
7.76

8.24
8.09
7.74
7.94
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H

1.29

1.46

Other

Me 2.66
0.77, 0.76
7.14
1.86

Me 2.66
0.74, 0.72
7.25
1.86

1.25

4.82
5.15
0.75, 0.69, Me 3.01
7.25, 7.21
1.85

1.32

5.16
5.00
0.86, 0.81
Ar 7.25, 7.14, Me
2.64
1.86

1.55, 1.32
0.97

1.50
0.75, 0.68
7.26, 7.20
1.84

NMR Chemical Shift Assignments (continued).

15 Lactam
Dapa
Ser
Ser
Leu
Phe
Ac
16  N-term
Mercap
Ser
Ser
Leu
Phe

NH



H

8.11
8.04
8.67
7.72
7.49

4.38
4.31
3.84
3.94
4.36

3.62, 2.85
3.79, 3.71
3.62
1.10, 1.25
3.21, 3.00

8.06
7.34
8.18
8.76

2.62, 2.34
4.18
4.26
3.88
4.54

2.87, 3.21
3.64
3.64
1.24
3.33, 2.83

H

Other
7.59
5.32

1.37

1.42

0.69, 0.76
7.20
1.84

4.98
5.09
0.74, 0.70
7.26, 7.20


Ac = N-terminal acetyl group. Pent = 5-aminopentanoic acid.
Dapa = 2,3-diaminopropanoic acid. Mercap = 3-mercaptopropanoic acid.
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